header logo image


Page 164«..1020..163164165166..170180..»

Complementary Protection May Be at Hand With a COVID-19-Preventing Nasal Spray – Newsweek

August 17th, 2021 1:53 am

Vaccinated citizens can still transmit the COVID-19 virus and its variants to other people. Salvacion USA Inc. is therefore excited to introduce the development of a complementary product, designed for adults 18 and older, it hopes could accompany COVID-19 vaccines to offer additional protection: a nasal spray to shield the nasal passages and prevent further viral transmission. (However, CDC guidelines should still be followed, and those who are eligible should receive the COVID-19 vaccination.)

COVID-19 vaccination numbers in the U.S. have now reached nearly 50 percent, and Americans are eager to resume life post-pandemic. However, as flu season approaches and the COVID-19 vaccines' efficacy and longevity have come under question, communities are increasingly concerned about the virus and its Delta and unknown variantsespecially as children return to school this fall. Experts have also speculated this pandemic could become endemic, cycling from season to season. For these reasons, we must continue to stay ahead of the rapidly updating situation and arrive at innovative strategies.

Salvacion's new technology is gaining momentum among the scientific community. The National Cancer Instituteestablished Nanotechnology Characterization Laboratory (NCL) recently selected Salvacion USA Inc. as one of its Assay Cascade awardees for Salvacion's nasal spray, trade name: COVIXYL-V. The announcement appeared in NCL's June 2021 quarterly newsletter, in which Salvacion noted, "COVIXYL-V is intended to reduce SARS-CoV-2 in nasal passages, a main point of entry for the virus in humans. Our unique virus-blocking product, optimized in collaboration with NCL, contains agents which block the virus from attaching to tissue and reducing the viral load in the tissue milieu."

According to NCL's announcement, "Nanomedicines accepted into the program will undergo a rigorous evaluation that may include sterility and endotoxin testing, physicochemical characterization, in vitro hemato- and immunotoxicity, and in vivo studies to evaluate safety, efficacy and pharmacokinetics. The studies are tailored to each individual nanomedicine and are designed to promote the clinical translation of these novel therapies."

Among Nanotechnology Characterization Laboratory's's five awardees, Salvacion is the only one working on a product intended to avert the spread of COVID-19. As an Assay Cascade awardee, NCL commits to funding Salvacion studies free of charge.

Ryan Hwang, a Salvacion spokesman, said, "Our product is preventative and protects nasal passages, halting transmission. Vaccines are developed to protect against COVID-19, but they are not designed to stop transmission. Our strategy is complementary to the effectiveness of vaccines by deterring COVID-19 infection by blocking the transmission."

Salvacion's clinical human trials are currently underway. In vitro and in vivo testing performed thus far suggested that the nasal spray inhibited 99.99 percent of COVID-19. This spray effectively blocked COVID-19 activity in the nasal passages of hamsters, the prime entry points for the virus. One study, performed by an independent BSL-3 laboratory (which, according to Public Health Emergency, is a lab "used to study infectious agents or toxins that may be transmitted through the air and cause potentially lethal infections"), showed that COVID-19 was 99.99 percent inactivated post-spray, with no clinical symptoms experienced by Syrian hamsters from the treatment. No adverse reactions were reported in the hamsters following administration. The data developed in this study showed that the nasal spray product was effective in neutralizing the virus within low concentrations. An additional barrier effect animal study undertaken at an independent laboratory also assessed the COVID-19 blocking effects of the nasal spray. It concluded that the spray created a physical barrier to block the viral particles from taking hold on the surface of the nasal passages. The testing was to prove the mechanism of the nasal spray is capable of blocking the transmission of COVID-19 by creating a physical barrier. The next step is the conducting of a human clinical trial, which is now underway. Salvacion is currently seeking an Emergency Use Authorization (EAU) for its COVIXYL-V nasal spray from the FDA.

This nasal spray is made of ingredients listed as GRAS, or "Generally Recognized As Safe," by the FDA. Unlike other products based on isopropyl alcohol currently being tested, it appears Salvacion's nasal spray could offer a unique blocking system with enhanced effectiveness at a very low concentration. A worldwide patent has been filed for this technology.

"Our nasal spray product may well be the key to moving back to a world that some have thought lost forever to the 'new normalcy,'" said Abdul Gaffar, a Salvacion chemist and recipient of the American Chemistry Society's Heroes of Chemistry Award, who invented this nasal spray.

The contents of this article are for informational purposes only and do not constitute medical advice. It's important to consult with your medical providers and the CDC before making any medical decisions or changes to your health plan, particularly with regard to COVID-19 and its variants.

Read this article:
Complementary Protection May Be at Hand With a COVID-19-Preventing Nasal Spray - Newsweek

Read More...

McMaster University researchers awarded more than $3M in Federal funds for projects – insauga.com

August 17th, 2021 1:53 am

Eleven researchers working out of Hamilton's McMaster University have been awarded almost $3.3 million from the Federal Government for projects deemed to be "on the cutting edge of science andinnovation."

On Wednesday (Aug. 11), Francois-Philippe Champagne, Minister of Innovation, Science and Industry, announced that more than $77 million had been earmarked to support 332 research infrastructure projects at 50 universities acrossCanada.

The funding, made possible through the Canada Foundation for Innovation's (CFI) John R. Evans Leaders Fund (JELF), is expected to help universities attract and retain topresearchers.

"From developing sustainable building materials to creating new laboratories based on Indigenous principles and community engagement, these awards support essential and urgent research," said CFI president and CEO Roseann O'Reilly Runte, in a pressrelease.

"With the necessary spaces and tools, Canada's researchers will play a meaningful role on the global stage and contribute significantly to the quality of life today and for generations tocome."

The more than $3 million going to Mac researchers will help advance their work in health, materials and electrificationresearch.

Projects at Mac that will benefit from the fundinginclude:

Faculty ofEngineering

Bilgen Berker, Electrical and Computer Engineering Project: An Acoustic Noise and Vibration Measurement Facility for Low-noise and High-efficiency Electric Motor DrivesAward:$200,000

Ryan Lewis, Engineering Physics Project: Advanced Epitaxial Nanostructures and Materials LaboratoryAward:$190,584

Zahra Keshavarz-Motamed, Mechanical Engineering Project: Developments of Diagnostic and Predictive Tools and Regulatory Device Testing Machines for Cardiovascular DiseasesAward:$185,000

Maureen Lagos Paredes, Materials Science & Engineering Project: Momentum-resolved EELS Spectroscopy of Beam-sensitive Nanoscale MaterialsAward:$387,788

Faculty of HealthSciences

Lisa Carlesso, Rehabilitation Science Project: Understanding Pain Mechanisms and Management in Neuromusculoskeletal RehabilitationAward:$129,000

Michael McGillion, Nursing Project: Improving Perioperative and canceR Outcomes Through Excellence and appliCation of Virtual Technologies (PROTECT) LabAward:$800,000

Ishac Nazy, Medicine Project: Investigating Novel Mechanisms in Immune-mediated Platelet DisordersAward:$160,000

Michael Surette, Medicine Project: Metagemomics and Genomics of the Microbiome, Infectious Disease and Host ResponseAward:$650,000

Faculty ofScience

Katherine Bujold, Chemistry & Chemical Biology Project: Establishment of Nucleic Acid Nanomedicine Laboratory at McMaster UniversityAward:$75,005

Katrina Choe, Psychology, Neuroscience & Behaviour Project: Neural Mechanisms Linking Autism-risk Genes with Impaired Social BehaviorAward:$400,000

Jeremy Walsh, Kinesiology Project: Integrative Psychophysiology Research LabAward:$100,000

A full list of research projects and funding recipients benefitting from this investment can be found on the CFI website.

Read more:
McMaster University researchers awarded more than $3M in Federal funds for projects - insauga.com

Read More...

MagForce AG announces results of 2021 Annual General Meeting and changes to the Supervisory Board – Yahoo Eurosport UK

August 17th, 2021 1:53 am

DGAP-News: MagForce AG / Key word(s): AGM/EGM12.08.2021 / 17:15 The issuer is solely responsible for the content of this announcement.

MagForce AG announces results of 2021 Annual General Meeting and changes to the Supervisory Board

Berlin, Germany, and Nevada, USA, August 12, 2021 - MagForce AG (Frankfurt, Scale, Xetra: MF6, ISIN: DE000A0HGQF5), a leading medical device company in the field of nanomedicine focused on oncology, today announced the results of the 2021 Annual General Meeting (AGM). Due to the COVID-19 pandemic, the meeting was held virtually, as in the previous year. In total, 44.5 percent of the share capital with voting rights was represented.

The Annual General Meeting approved resolution items 2 to 5 as well as 7, 8 and 10 - most of them with a significant majority. Resolution item 6 (Authorized Capital 2021) did not receive the required qualified majority. Norbert Neef, Chairman of the Supervisory Board, informed the Annual General Meeting that he resigns from office effective as of the end of the AGM. Thus, the vote on agenda item 9 was not applicable. Following the suggestion of the supplementary motion of shareholder Avalon Capital One GmbH dated July 29, 2021, Stefan Schtze, attorney and Managing Director of C3 Management GmbH, was elected to the Supervisory Board from the end of this AGM until the end of the AGM that resolves on the ratification of the actions of the members of the Supervisory Board for fiscal year 2021. The Supervisory Board of MagForce AG, which also includes Klemens Hallmann and Aaron Weaver, will hold a constituent meeting shortly to vote on the new chair.

Ben Lipps, CEO of MagForce AG and MagForce USA, Inc.: "From the Management as well as the employees of MagForce, I would like to express my sincere gratitude. Norbert has overseen the Company through its formative years and contributed significantly to the constructive cooperation between the Supervisory Board and the Executive Board that has supported the important decisions in corporate strategy and direction. As a result we have two unique and effective treatment options for glioblastoma and focal intermediate risk prostate cancer. The Management Board wishes Norbert every success in his professional as well as private future. At the same time, we welcome Mr Schtze as new member of the Supervisory Board and look forward to working together to achieve further important milestones for MagForce."

Additional information on the 2021 Annual General Meeting 2021, including detailed voting results, the video address by CEO Ben J. Lipps, as well as the Management presentation on current operational developments, the overview of fiscal year 2020 and outlook for the current year, are available on the Company's website at https://www.magforce.com/en/home/for-press-investors/#general_meetings.

About MagForce AG and MagForce USA, Inc.

MagForce AG, listed in the Scale segment of the Frankfurt Stock Exchange (MF6, ISIN: DE000A0HGQF5), together with its subsidiary MagForce USA, Inc., is a leading medical device company in the field of nanomedicine focused on oncology. The Group's proprietary NanoTherm(R) therapy system enables the targeted treatment of solid tumors through the intratumoral generation of heat via activation of superparamagnetic nanoparticles.

NanoTherm(R), NanoPlan(R), and NanoActivator(R) are components of the therapy and have received EU-wide regulatory approval as medical devices for the treatment of brain tumors. MagForce, NanoTherm, NanoPlan, and NanoActivator are trademarks of MagForce AG in selected countries.

For more information, please visit: http://www.magforce.comGet to know our Technology: video (You Tube)Stay informed and subscribe to our mailing list

Contact:MagForce AGBarbara von FrankenbergVice President Communications & Investor RelationsT +49-30-308380-77E-Mail: bfrankenberg@magforce.com

Disclaimer

This release may contain forward-looking statements and information which may be identified by terms such as "expects", "aims", "anticipates", "intends", "plans", "believes", "seeks", "estimates" or "will". Such forward-looking statements are based on our current expectations and certain assumptions, which may be subject to a variety of risks and uncertainties. The results actually achieved by MagForce AG may substantially differ from these forward-looking statements. MagForce AG assumes no obligation to update these forward-looking statements or to correct them in case of developments, which differ from those, anticipated.

12.08.2021 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at http://www.dgap.de

Original post:
MagForce AG announces results of 2021 Annual General Meeting and changes to the Supervisory Board - Yahoo Eurosport UK

Read More...

Stages of Diabetes: Stages, Symptoms, and Treatments – Healthline

August 17th, 2021 1:52 am

Diabetes is an umbrella term for three primary conditions: type 1 diabetes, type 2 diabetes, and gestational diabetes. According to guidelines established by experts in the field, there are multiple stages of diabetes, each of which are defined by physiological changes within the body.

In this article, well explore the stages of type 1 and type 2 diabetes as defined by diabetes experts, as well as information about long-term diabetes management.

Within the past decade, professional organizations, like the American Diabetes Association (ADA) and the American Association of Clinical Endocrinologists (AACE), have created guidelines that outline the various stages of diabetes development.

According to the literature on these guidelines, understanding the various stages of diabetes can allow physicians and patients to take a more comprehensive approach to preventive care and disease management.

Below, weve outlined the various stages of beta cell dysfunction, type 1 diabetes, and type 2 diabetes, as established by current experts in the field of diabetes research.

In 2015, the ADA released a joint statement with the JDRF and Endocrine Society outlining the various stages of type 1 diabetes. Using the guideline below, clinicians can more easily diagnose this condition at an earlier stage, even when symptoms might not be present.

Its important to note that type 1 diabetes is an autoimmune disease where the immune system attacks and destroys beta cells in the pancreas, which are responsible for producing insulin.

In this stage, genetic analysis can help identify underlying genotypes that are commonly associated with type 1 diabetes.

According to the research, a specific region on chromosome six called the HLA region is associated with up to 50 percent of the risk for developing this condition. Other factors, like having a sibling or close relative with type 1 diabetes, can also increase disease risk.

In this stage, at least one diabetes-related autoantibody is present in the blood. At this point, these autoantibodies have already begun to attack the beta cells in the pancreas. But blood sugar levels still remain within the normal range, and no symptoms are present.

In this stage, at least two or more diabetes-related autoantibodies are present in the blood. As the beta cells continue to be destroyed by the immune system, a lack of insulin leads to rising blood sugar levels due to glucose intolerance. Although beta cell dysfunction is more serious at this stage, there are still no symptoms yet.

In this stage, theres a significant loss of beta cells due to autoimmunity and symptoms are present, resulting in a type 1 diabetes diagnosis. During this stage, the symptoms of type 1 diabetes may include:

In 2018, the AACE created the dysglycemia-based chronic disease (DBCD) multimorbidity care model. Much like the previous guidelines above from 2015, the DBCD care model helps clinicians take preventative steps to reduce type 2 diabetes complications.

This stage, defined as insulin resistance, is where muscle, fat, and liver cells become resistant to insulin and have trouble bringing glucose into the cell. But the pancreas compensates for this by producing more insulin, which helps keep blood sugar levels within normal range.

In this stage, also known as prediabetes, cells become so insulin resistant that the extra insulin isnt enough to lower blood sugar levels back to normal. In some cases, beta cell dysfunction may also be present. During this stage, blood glucose levels remain higher than normal, but not high enough to be classified as diabetes.

In this stage, blood sugar levels remain abnormally high, leading to a diagnosis of type 2 diabetes. Both insulin resistance and beta cell dysfunction can lead to high blood sugar levels in type 2 diabetes. Without treatment, these elevated levels can cause long-term damage to the body.

In this stage, vascular complications can occur as a result of high blood sugar. As blood sugar levels remain high, damage can occur within the vascular system, leading to potential complications like:

While end-stage diabetes isnt a commonly used term, diabetes can lead to whats known as end-stage diabetic complications, or advanced complications. In people with diabetes, advanced complications, like end-stage renal disease, occur after many years of living with diabetes.

A study from 2019 found that microvascular complications from diabetes, like nephropathy, increase risk for cardiovascular events and death in people with type 1.

While theres no cure for diabetes, it can be managed through the appropriate treatment, which may include medications, dietary changes, and lifestyle interventions.

Although it can feel overwhelming to manage a chronic health condition like diabetes, your healthcare team is there to help you create a diabetes treatment plan that works best for you.

If youre concerned about managing your diabetes, the first step is to reach out to your doctor or care team to create a diabetes treatment plan. Depending on your diagnosis and personal needs, your treatment plan may include reaching out to:

According to experts in the field of diabetes research, diabetes staging plays an important role in the prevention, diagnosis, and treatment of diabetes. Understanding the various stages of both type 1 and type 2 diabetes allows physicians and patients to see the progression of the disease so that treatment and long-term management can be improved.

If youve been diagnosed with diabetes, its important to stay educated about your condition so that you can more easily manage it in the long-term.

Go here to see the original:
Stages of Diabetes: Stages, Symptoms, and Treatments - Healthline

Read More...

Oramed Announces Publication of Oral Insulin Study in Peer-Reviewed Journal: Diabetes, Obesity, and Metabolism – Yahoo Finance

August 17th, 2021 1:52 am

NEW YORK, Aug. 16, 2021 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP), (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, today announced that Diabetes, Obesity, and Metabolism, has published an original article titled "Efficacy and safety of 28-day treatment with oral insulin (ORMD-0801) in patients with type 2 diabetes mellitus - A randomized placebo-controlled trial" authored by Dr. Roy Eldor, Dr. Joel Neutel, Kenneth Homer and Oramed's Chief Scientific Officer, Dr. Miriam Kidron.

Oramed Pharmaceuticals Logo

The article presents the results of a trial that assessed the safety and efficacy of Oramed's lead drug candidate ORMD-0801 in type 2 diabetes (T2DM). The trial met its primary endpoint and found that in patients with T2DM, bedtime ORMD-0801 curbed increases in night-time glycemia, 24-hour glycemia, and HbA1c without increasing the risk of hypoglycemia or safety events as compared to the control arm.

"I'm proud and excited that this paper, exploring the interesting and important results of Oramed's Phase 2 study of oral insulin has been published by Diabetes, Obesity and Metabolism," said Roy Eldor, M.D. Ph.D., Director, Diabetes Unit, Institute of Endocrinology, Metabolism & Hypertension, Tel-Aviv Sourasky Medical Center, and a member of Oramed's Scientific Advisory Board.

About Oramed Pharmaceuticals

Oramed Pharmaceuticals (Nasdaq/TASE: ORMP) is a platform technology pioneer in the field of oral delivery solutions for drugs currently delivered via injection. Established in 2006, with offices in the United States and Israel, Oramed has developed a novel Protein Oral Delivery (POD) technology. Oramed is seeking to transform the treatment of diabetes through its proprietary lead candidate, ORMD-0801, which is being evaluated in two pivotal Phase 3 studies and has the potential to be the first commercial oral insulin capsule for the treatment of diabetes. In addition, Oramed is developing an oral GLP-1 (Glucagon-like peptide-1) analog capsule.

Story continues

For more information, please visit http://www.oramed.com.

Forward-looking statements: This press release contains forward-looking statements. For example, we are using forward-looking statements when we discuss the potential efficacy and safety of ORMD-0801, the ability of Oramed to transform the treatment of diabetes and the potential of ORMD-0801 to be the first commercial oral insulin capsule for the treatment of diabetes. In addition, historic results of scientific research and clinical trials do not guarantee that the conclusions of future research or trials will suggest identical or even similar conclusions. These forward-looking statements are based on the current expectations of the management of Oramed only, and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements, including the risks and uncertainties related to the progress, timing, cost, and results of clinical trials and product development programs; difficulties or delays in obtaining regulatory approval or patent protection for our product candidates; competition from other pharmaceutical or biotechnology companies; and our ability to obtain additional funding required to conduct our research, development and commercialization activities. In addition, the following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements: changes in technology and market requirements; delays or obstacles in launching our clinical trials; changes in legislation; inability to timely develop and introduce new technologies, products and applications; lack of validation of our technology as we progress further and lack of acceptance of our methods by the scientific community; inability to retain or attract key employees whose knowledge is essential to the development of our products; unforeseen scientific difficulties that may develop with our process; greater cost of final product than anticipated; loss of market share and pressure on pricing resulting from competition; laboratory results that do not translate to equally good results in real settings; our patents may not be sufficient; and finally that products may harm recipients, all of which could cause the actual results or performance of Oramed to differ materially from those contemplated in such forward-looking statements. Except as otherwise required by law, Oramed undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. For a more detailed description of the risks and uncertainties affecting Oramed, reference is made to Oramed's reports filed from time to time with the Securities and Exchange Commission.

Logo - https://mma.prnewswire.com/media/647544/Oramed_Pharmaceuticals_Logo.jpg

Company ContactJosh Hexter +1-844-9-ORAMEDjosh@oramed.com

Cision

View original content:https://www.prnewswire.com/news-releases/oramed-announces-publication-of-oral-insulin-study-in-peer-reviewed-journal-diabetes-obesity-and-metabolism-301355754.html

SOURCE Oramed Pharmaceuticals Inc.

Read more from the original source:
Oramed Announces Publication of Oral Insulin Study in Peer-Reviewed Journal: Diabetes, Obesity, and Metabolism - Yahoo Finance

Read More...

Diabetes cases soar by 60% in just five years in under 25s know the signs… – The Sun

August 17th, 2021 1:52 am

CASES of diabetes are on the rise in young people, driven by the obesity crisis.

Being aware of the signs could prevent serious complications from the disease if a child or young person gets an early diagnosis.

1

Diabetes is a serious condition which needs lifelong management.

Unfortunately, type 2 diabetes - which accounts for 90 per cent of all cases - is accelerating as a result of factors including obesity.

More often than not, the condition is triggered by poor lifestyle habits like eating too much unhealthy food or not exercising.

The effects are now being seen in children, some younger than 12 years old, who previously were more likely to get type 1 diabetes, which is genetic.

New figures show a 60 per cent increase in under 25s with type 2 diabetes being treated at paediatric diabetes units in England and Wales over five years.

There were 866 under-25s who got treatment in 2019/20 compared with the 322 in 2014/15, according to the stats published by Royal College of Paediatrics and Child Health.

Just over 84 per cent of the patients were registered as obese, broadly in line with previous years.

Nikki Joule, policy manager at Diabetes UK, said: Type 2 diabetes is no longer just a condition found in older people; it can affect any age.

We also know that type 2 diabetes is likely to have more severe and acute consequences, if they develop it as children especially if they do not have access to the right specialist treatment and support.

Childhood obesity is the main driver behind the rise in cases."

It comes after a new report revealed almost 1,600 children under 19 in England have type 2 diabetes.

Diabetes UK warned that the NHS Digital data on August 12 confirms a recent growing trend of serious health conditions related to obesity that are becoming more prevalent in a younger demographic than ever before.

It highlighted nearly a third of children aged two to 15 years old were overweight or obese.

Chief executive Chris Askew said the figures were a worrying wake-up call.

NHS Digital data shows that people who get diabetes under 40 years old are more likely to:

Symptoms of diabetes can go completely missed because people think they are caused by something else.

Or their symptoms dont necessarily make them feel unwell, so they are not even acknowledged.

The most common early signs of type 2 diabetes are frequent urination, extreme thirst, and persistent hunger.

You should visit your GP if you are:

There are other symptoms that may alert you to this disease.

These include:

In children

Dan Howarth, Head of Care at Diabetes UK, said: The symptoms of diabetes needing the toilet more often than usual, feeling more tired or thirsty than normal, and unexplained weight loss are the same for people of all ages, and with all types of diabetes.

"Symptoms of type 1 diabetes develop very quickly, whereas type 2 diabetes symptoms come on more slowly.

"In children and young people with type 2 diabetes, symptoms may be less noticeable, with cases often going undetected."

But more specific problems to look out for are:

If your child is very overweight, the NHS says there are things you can to help them get to a healthy weight.

This includes upping exercise, keeping portions to child-sized, and eating healthier foods.

Exercise doesnt need to be any more than playing it, riding a bike, swimming or using a playground, so long as they are happy and moving.

All children need about 60 minutes of physical activity a day for good health, but it doesn't need to be all at once, the NHS says.

Food wise, children should avoid eating too much of the same things that cause weight gain in adults - sweets, chocolate, crisps and cakes.

Its important that as a parent, you also act as a good role model and try and get the whole family involved, so it doesnt feel like your child is targeted.

It can be a scary time if your child is diagnosed with diabetes, but doctors will be there to support you.

Your child will get a treatment plan that you as a parent will be involved with administering - including insulin injections.

You will also have to keep a close eye on your child's glucose levels to make sure they dont become dangerously low or high.

On top of this, children with diabetes will need to eat a healthy diet and exercise is considered incredibly important, Diabetes UK says.

Dan, Head of Care, said: Some people with type 2 diabetes can put their diabetes into remission through a combination of weight loss and lifestyle changes.

"While research into remission and young people with type 2 is ongoing, we know that by making lifestyle changes such as keeping physically active and eating healthily, families and young people with type 2 diabetes can increase their chances of remission, reduce their risk of diabetes-related complications risk and improve their overall health.

For more information about diabetes, visit diabetes.org.uk

Read more from the original source:
Diabetes cases soar by 60% in just five years in under 25s know the signs... - The Sun

Read More...

Diabetes startup brews up $11M after ‘serendipitous spill’ led to creation of new CGM tech – FierceBiotech

August 17th, 2021 1:52 am

Many of the most groundbreaking discoveries have happened accidentally: The microwave oven, for one, was developed after physicist Percy Spencer noticed a chocolate bar in his pocket had melted while he was experimenting with a magnetron. Penicillin was born out of the bacteria-killing mold that grew on a petri dish while biologist Alexander Fleming was on vacation.

Perhaps aiming to join their ranks is Israeli startup Hagar, with itsGWave technology that measures blood sugar levels using noninvasive radio waves rather than an implanted sensor or repeated fingersticks.

According to Hagar lore, the technology came about after Geri Waintraub, the companys co-founder and chief technology officer, accidentally spilled a cup of tea on a radio frequency device during a separate research project and concluded that the ensuing reaction was caused by the sugar in his tea. Thus, GWave was born.

RELATED: Dexcom gets FDA go-ahead to pair diabetes data with Garmin, Livongo and more through 3rd-party APIs

The first generation of the GWave sensor is a device about a third the size of a standard smartphone,inserted into a ceramic bracelet. It uses Bluetooth to transmit its glucose readings to an accompanyingmobile app that tracks readings and alerts users to fluctuations in their blood sugar levels.

While radio waves are a form of electromagnetic radiation,GWave produces significantly less amounts than a smartphone, according to Hagar.

A proof-of-concept study found the company's radio frequency technology was able to continuously measure glucose levels with at least 90% accuracy, compared to the estimated 70% rate for traditional continuous glucose monitors.

According to the company, that difference stems from the fact that Hagars system directly measures glucose in the blood in real time. Other CGMs may use a sensor implanted under the skin to take measurements from the interstitial fluid between cells and may often have to be calibrated throughout the day with routine fingerstick blood tests.

RELATED: One Drop poaches Sanofi's head of diabetes innovation to bring CGM biosensor to market

Backed by those promising results, and with Hagar now planning to launch clinical trials to pursue FDA approval of the GWave system, the company has raised $11.7 million in series B funding.

The financing was led by Columbia Pacific and comes shortly after Hagar closed its series A, which brought in$4.4 million just last March. Those back-to-back funding rounds bring the companys lifetime funding to just over $17 million.

With 8.3% of the U.S. population living with diabetes today, that number is projected to rise to one in three adults by 2050. Finding a way to monitor glucose levels in the bloodcontinuously, painlessly and easilyis life-changing for those living with diabetes, and we are thrilled that our partners at Columbia Pacific are helping us in this journey, said CEO Guy Zur.

Next up, along with plotting out clinical trials of its technology, Hagar will continue developing the second-generation GWave device. In that iteration, the sensor will be embedded into a smartwatch that will be able to display the readings collected by the GWave mobile app.

View original post here:
Diabetes startup brews up $11M after 'serendipitous spill' led to creation of new CGM tech - FierceBiotech

Read More...

Diabetes Canada and LIFT session team up to support Canadians living with diabetes – Canada NewsWire

August 17th, 2021 1:52 am

MONTREAL, Aug. 16, 2021 /CNW Telbec/ -LIFT session, a leading Canadian digital fitness and wellness platform, has entered into a partnership with Diabetes Canada to bolster fundraising for their annual event Lace Up to End Diabetes. Lace Up to End Diabetes, presented by GMS Health & Travel Insurance, is a virtual walk, run, dance your way to 10K campaign taking place from Sept 1-30, 2021. This year the event also includes a 100KM fitness challenge in support of the 100th anniversary of the discovery of insulin.

The partnership with LIFT session will help drive this fundraising initiative and encourage more people to engage in their physical and mental wellbeing. By reaching certain fundraising goals, participants will get exclusive access to LIFT session's best in class employee wellness solution, including live coach chat, AI based workouts and 3 live online group training sessions.

Furthermore, LIFT session and Diabetes Canada plan on exploring future opportunities to build on their partnership through innovative digital wellness fundraising strategies.

"Diabetes Canada is excited to offer this digital fitness opportunity to Lace Up participants" Nicole Holder-Dulson, Regional Director, Ontario. "Fitness and wellness have historically been a powerful tool in fundraising, and a digital offering makes fundraising borderless. LIFT was the ideal partner, as the platform ensures users receive curated workouts specific to their goals and fitness levels, with live support from wellness experts.

"Our mission at LIFT session has always been to increase the overall health of our society." saysRaffi Tchakmakjian, CEO of LIFT session. "Diabetes is a disease that affects us all and this partnership is just the first step in our efforts to help end diabetes. It's an honour for us to help power a quintessential organization like Diabetes Canada in their ambitions to expand their fundraising reach through digital fitness."

To learn more about the service, please visit Lace-up's website at:Lace-up by Diabetes Canada.

ABOUT DIABETES CANADADiabetes Canadais the nation's most trusted provider of diabetes education, research, resources, and services. We've helped millions of Canadians affected by diabetes understand it, manage it, and combat complications since 1953.

ABOUT LIFT SESSIONLIFT session's goal is to make top fitness coaching and sessions accessible to anyone, from any location and on-demand. By offering services through wellness providers and businesses, LIFT session offers its online fitness platform to millions of customers globally.

LIFT session's customers are invited to participate in automated AI based workout sessions, live group and one-on-one online training sessions, either on their own or through highly engaging LIFT corporate challenges. The platform offers a wide range of fitness classes from high intensity interval training to Pilates, yoga, dynamic stretching and mobility. LIFT session helps members to achieve their personal goal whether they are training for a competition, preparing for an event, looking to shed a few pounds, or just looking to build a healthy lifestyle. Follow LIFT session on Instagram and Facebook @liftsession.

SOURCE LIFT Digital Inc.

For further information: David Sciacca, [emailprotected], (514) 994-8058

liftsession.com

See the rest here:
Diabetes Canada and LIFT session team up to support Canadians living with diabetes - Canada NewsWire

Read More...

Hallberg given Sagamore of the Wabash for work in diabetes research – Journal & Courier

August 17th, 2021 1:52 am

LAFAYETTE, Ind. Dr. Sarah Hallberg, the medical director at Virta Health, was recently awarded the Sagamore of the Wabash award for her work in diabetes research.

The Sagamore of the Wabash first started in 1946 with then-Indiana Gov. Ralph Gates. Gates was on his way to a conference of Kentucky, Indiana and Ohio officials when he learned that the then-Kentucky governor, Simeon S. Willis,planned to award gates the Kentucky Colonel, the state's highest honor.

Not to be outdone by Kentucky, Gates named Willis the first recipient of the Sagamore of the Wabash. Since then, thousandsof people have received this honor, including David Letterman, Muhammed Ali, and now, Dr. Hallberg.

According to its description, TheSagamore of the Wabash is the "highest honor, which the governor of Indiana bestows. It is a personal tribute usually given to those who have rendered a distinguished service to the state or to the governor."

"Among these who have received Sagamores have been astronauts, presidents, ambassadors, artists, musicians, politicians, and ordinary citizens who have contributed greatly to our Hoosier heritage."

Wabash Township: Trustee proposes increasing her salary in 2022

There is no official record of how many have been presented with this honor, as each governor has kept their choicesdocumented using different methods.

"I was just floored," Hallberg said about she show felt when she won the award. "I'm so lucky to have had this career where I can really help people improve their lives, and be a real patient advocate."

Before joining Virta Health, Hallberg worked at IU Health Arnett Hospital where she founded the Supervised Weight Loss Program.This clinic served as the host for Virta's clinical trials.

"What I came across was carbohydrate restriction," Hallberg said, "and we opened the clinic as a carbohydrate-restricted clinic. That was the nutrition intervention that we were using. What we were seeing in patients was just remarkable. When we were putting them on a therapeutic, carbohydrate-restrictive diet, their diabetes was going away."

These clinics took place about a decade ago, according to Hallberg, and up until thatpoint, Type 2 Diabetes was seen as a chronic and progressive disease. Seeing the effects a carb-restricted diet has on patients motivated Hallberg to expand her research to beyond her clinic in central Indiana.

2020 U.S. Census: Tippecanoe County population increased, more diverse

Dr. Stephen D. Phinney, the chief innovation officer and co-founder of Virta Health, and Hallberg have worked and continue to work on a number of published papers together to help get the news of reversible diabetes through carb-restriction out there.

"The biggest thing is that this study, in central Indiana, changed the American Diabetes Association guidelines," Hallberg said. "We did this research that impacted the guidelines that haveimpacted so many Americans. And that happened here in central Indiana."

Four years ago, Hallberg was diagnosed with advanced lung cancer. She explained howher diagnosis and her work experience being a patient advocate both affected her.

"Being a patient advocate for so long and just wantingto empower and teach them (the patients) with the science," Hallberg said, "really came into play for me four years ago when I became a patient myself. So all the advocacy I've done for my patients, I was really fortunate in that I could turn that into being an advocate for myself with an advanced cancer diagnosis."

Margaret Troupis a reporter for the Journal & Courier. Email herat mtroup@jconline.com and follow heron Twitter@MargaretTroup2

The rest is here:
Hallberg given Sagamore of the Wabash for work in diabetes research - Journal & Courier

Read More...

New Stem cell conveying hydrogel could assist the heart with recuperating myocardial ischemia – Microbioz India

August 17th, 2021 1:52 am

When blood vessels that feed the heart become blocked, damage to the heart muscle can occur and this can affect cardiac function. By stimulating the formation of new blood vessels, a new stem-cell-carrying gel helps mice overcome this condition called myocardial Infarction. The stem cell delivery system was developed by scientists from Kansai University, Japan. It is published in Science and Technology of Advanced Materials.

The hydrogel acts like a scaffold to hold the stem cells in place at injection site and keep them alive longer. The stem cells release cytokines, which stimulate the formation blood vessels and help the heart to recover. The gel is biodegradable so that it eventually dissolves and can be discarded by the body. Image credit: Kansai University

In their application, the team used stem cells from fat tissue. These stem cells, also known as adipose derived stem cells, have been used in the treatment of damaged cardiac tissue due to reduced blood flow. This is called myocardial Ischemia. Once injected into damaged tissue, the stem cells are supposed to release stimulants that can help regenerate blood vessels. However, they are not able to be retained in the tissue or survive long enough. Scientists have also found that injecting biodegradable hydrogels, which are cell-free, into damaged heart tissue can help partial recovery.

They first created hydrogels that could hold stem cells in place longer at the site where there is tissue damage. They are best used at room temperature. This allows you to easily mix the stem cells. The solution reacts with the body to heat and transforms into a gel when it is injected into the organ.

One hydrogel was particularly good at keeping its gel state. It was made from a mixture of molecules called tri-PCG with acrolyl group attached. The tri-PCG-acryl mixture was then combined with a polythiol derivative.

The team also added stem cells from adipose tissue to the hydrogel. They then observed how long they lived in petri dishes as well as the production of different genes and substances.

The stem cells were able to survive in our injectable hydrogel and released molecules that stimulate blood vessel formation, improving heart function and making it effective for treatment of ischemic heart.

Yuichi Ohya, Bioengineer, Kansai University

After confirming safety, the team plans to next test the therapy on larger animals and then conduct clinical trials in humans. They plan to use their injectable hydrogel for immune cells to treat cancer and in vaccines against viral infections.

Source:

Journal reference:

Yoshizaki, Y.,et al.(2021) Cellular therapy for myocardial ischemia using a temperature-responsive biodegradable injectable polymer system with adipose-derived stem cells.Science and Technology of Advanced Materials.doi.org/10.1080/14686996.2021.1938212.

Read the original here:
New Stem cell conveying hydrogel could assist the heart with recuperating myocardial ischemia - Microbioz India

Read More...

Participants Diagnosis Halts Gene Therapy Clinical Trial – The Scientist

August 17th, 2021 1:52 am

Aclinical trial testing a novel gene therapy for a rare neurological disease has been put on hold after one of the participants in a Phase 3 trial developed a bone marrow disorder that can lead to cancer. The pause, announced Monday by the trials sponsor, bluebird bio, and mandated by the US Food and Drug Administration (FDA), was taken out of an abundance of caution, the companys president of rare genetic diseases, Andrew Obenshain, said in a recent quarterly call.

The therapy targets cerebral adrenoleukodystrophy, which is caused by a mutation in the gene for an enzyme called adrenoleukodystrophy protein (ALDP) that breaks down fats. The mutation causes fat to build up in the brain, where it breaks down the insulating myelin that allows neurons to communicate with one another. Because the gene is on the X chromosome, women typically have a least one good copy, so the disease primarily strikes men. Left untreated, it causes damage to hearing, vision, cognition, and coordination. It is often fatal.

Bluebirds gene therapy uses an engineered lentivirus to correct the mutation associated with the disease. Lentiviruses belong to the same family as HIVretrovirusesand have been widely used in gene therapies and other medical applications for many years. While other virus-based platforms using retroviruses had previously been linked to cancer among patients, it is only recently that a lentivirus has been implicated in such an outcome: in February of this year, bluebird bio paused another trial, one for a blood disorder, after two patients developed leukemia-like cancer, Sciencereports, although it was later determined that the virus was likely not the cause, and the trial resumed.

Most in the field were hoping that we would not see such an event with lentiviral vectors, Harry Malech, a gene therapy researcher at the National Institutes of Health, tells Science, adding, I dont think anybodys been . . . saying this couldnt happen.

The cerebral adrenoleukodystrophy therapy involves taking samples of a patients bone marrow and treating the stem cells therein with the modified virus that contains a corrected copy of the gene that encodes ALDP. After a round of chemotherapy to reduce the persons bone marrow cells, the treated cells are infused back into the patient. Thereafter, the patients stem cells produce healthy blood cells with a functional copy of the gene for ALDP. The therapy entered the market in Europe last month following a previous safety and efficacy trial that included 32 patients. A second trial, the one that has now been paused, was set to finish in 2024.

Speaking on the call, bluebird bios Chief Scientific Officer Philip Gregory said that one patient in the second trial developed myelodysplastic syndrome (MDS), a blood disorder that sometimes leads to leukemia, and another two had abnormal bone marrow cells that could progress to MDS. When scientists examined their cells, they found lentiviral DNA inserted at a site in the genome that has previously been linked to MDS in retrovirus-based therapies, suggesting that the virus may have caused the changes.

Specifically, Gregory said the issue is likely caused by the virus promoter, the DNA sequence that turns on the therapeutic copy of the gene. To ensure the gene produces enough ALDP in the brain to be an effective treatment, the researchers needed a strong promoter, but as a consequence, the promoter had off-target effects, turning on other genes in the area around the mutation, including cancer genes, Gregory speculated.

Donald Kohn, a gene therapy researcher at the University of California, Los Angeles, who helped design the viral vector, tells Sciencethat in the time since bluebird bio first began developing the therapy, researchers have identified other promoters that might be able to do the job with a lower risk of causing cancer. He adds that this particular incident shouldnt preclude scientists from pursuing other lentivirus treatments, as the issue seems to come down to design, and Kohn doesnt know of any other lentivirus therapies that use the same type of promoter.

Panam Malik, a hematologist at Cincinnati Childrens Hospital who was not involved in the work, similarly tells Science that virus-based platforms should be highlighted for the good they have done. This is a severe adverse event, she says, but adds, we should never lose sight of the fact that so many patients . . . have been helped. Despite this rare incident, the findings could help scientists and researchers design safer and better vectors for the future.

Continued here:
Participants Diagnosis Halts Gene Therapy Clinical Trial - The Scientist

Read More...

The Involuted Palate, or the Savage Crinkle of Future Snacks – lareviewofbooks

August 17th, 2021 1:52 am

AUGUST 11, 2021

FOR THE ARCHITECTURAL HISTORIAN and critic Reyner Banham, the bag of potato chips (or crisps as he, an Englishman, put it) was a remarkable technological innovation. But it was an emotional object rather than a practical one. The sound of the bag crinkling and tearing as you ripped it open and consumed every greasy chip and then the shards at the bottom, expressed the temper of the late 20th century: Its the first and most familiar of Total-Destructo products and probably sublimates more aggression per annum than any quantity of dramaturgical catharsis, Banham wrote in his short essay The Crisp at the Crossroads (1970). Banham speculated about the possibilities for flavored chips: not just cheese-and-onion or barbecued bacon, but toad in the hole, crme de menthe, and more, all of them flavor stations along the expanding snacking frontier. But flavor seemed to interest him less than form. The relationship between chip and bag seemed to him almost vernacular: the bag of chips was like some survivor from a lost golden age of peasant technologies that have matured long in the wood and hand: the oar, the axe, the rolling pin. The chip glows golden when you hold it up to the light but it is unlike the oar, axe, or rolling pin, because its vernacular quality stems from the way it pairs with its packaging, the proper use of both involving a crinkling burst. The chip is an impractical food if the task is to get the most nutrition possible out of the potato; but if the task is to pleasurably wreck something, then the chip-and-bag is very good design indeed.

Fifty years later, the chip retains its basic shape, although some chips are now chili mango flavored. And the world of snacking R-and-D has not run out of steam. Entrepreneurs, working to transform food through technology, seem to promise new innovations every day, not all of them intended as mere snacks. There are pea protein puffs, and new kinds of plant-based burgers, and bunches of kale leaves grown hydroponically in vertical farms. The most ambitious of them all, the dream of growing meat in labs, hovers at the horizon, gaining headline coverage as companies promise to produce it soon but cultured meat never quite arrives in the supermarkets. The entrepreneurs call all these things innovations. But what if the best metaphor for describing new food-tech products was not innovation but involution? That latter term stems from the Latin involutio and carries the meaning of curling inwards (as a chip curls) but has more common meanings, which the OED provides: the state of being complicated; the shrinkage of old or inactive tissue in the body; a mathematical function, transformation, or operator that is equal to its inverse, or in other words, that continues to be itself when applied to itself. This should sound counterintuitive, for we are used to thinking of technological changes as introducing novelty into a system, perhaps changing that system fundamentally, rather than causing it to curl in on itself. In any case, involution may seem like a lofty term to apply to crunchy protein bars made with cricket flour, ersatz meat made by extruding pea protein, or powdered algae, but I will argue for the terms explanatory power bite by bite.

In his 1936 essay Loose Ends of a Theory on the Individual Pattern and Involution in Primitive Society, the anthropologist Alexander A. Goldenweiser put involution on anthropologys map. While meditating on the relationship between individual expression and cultural patterns, Goldenweiser used involution to describe an enduring condition in which patterns both in the sense of physical symbols but also forms of social behavior run through every aspect of a human communitys life, providing both a fabric of meaning and a limiting, even restrictive force. In primitive societies, Goldenweiser wrote, pattern is particularly conspicuous in rituals and the forms of religious objects, where the tenacity of pattern is enhanced by social inertia or a sacred halo. Pattern limits development, and Goldenweiser seemed to imply that an intimate relation with pattern was part of what kept primitive societies primitive. It inhibited the technical, social, and intellectual developments that could eventually lead to modernization.

But patterns also set limits in a more positive sense, as a canvas edge or a frame establishes the boundary for a painting. Thus Goldenweiser characterized the traditional art of the Maori, in which simple units of design recombine in multiple ways within a delimited space: The inevitable result is progressive complication, variety within uniformity, virtuosity within monotony. This, too, is involution. Involution wasnt limited to primitive contexts; Goldenweiser also found its inward curling in late Gothic art, whose structures and component parts may be fixed but still express play and creativity in elaborations on basic themes. But Goldenweiser saw involutions limits as ultimately negative:

Expansive creativeness having dried up at the source, a special kind of virtuosity takes its place, a sort of technical hairsplitting. No longer capable of genuine procreation, art here, like a seedless orange, breeds within itself, crowding its inner structure with the pale specters of unborn generations.

Like a seedless orange? Or like a protein bar made with cricket flour, its basic design already set by the architects of snacking, but filled with the bodies of insects? Crunch! Complexity. Crunch! Sameness.

Larissa Zimberoff, in her admirably skeptical book Technically Food: Inside Silicon Valleys Mission to Change What We Eat, describes the contemporary food-tech nexus, surveying a wide range of startup companies, mostly based in the San Francisco Bay Area. She interviews dozens of entrepreneurs, encountering them at tech conferences or in the warehouses and labs where they try to grow the future. She hears their pitches and then examines those pitches to see if they survive close scrutiny. Many of Zimberoffs entrepreneurs claim that their products will replace existing foods that are environmentally unsustainable or cruel to nonhuman animals. Their mission, then, is one of supersession. What if you could eliminate animal agriculture, with its massive environmental footprint and relatively inefficient transformation of plants into animal protein? Sensitive to concerns about the environment, and about animal cruelty, Zimberoff keeps human health at the books center: are these new foods really going to be better for us, especially given that so many of them are ultra-processed, a category linked to bad health outcomes? How about the well-known plant-based Impossible and Beyond Meat burgers? They are far more fatty and caloric than, say, a meal of chickpeas. Coconut oil, a key ingredient used in most plant-based meat, is about 90 percent saturated fat. Memorably, Zimberoff compares the creation of these burgers to fabricating a Slim Jim, which is made from chicken scraps through the same technique, extrusion. Are these different products? Yes. Are they similarly made? Yes. Zimberoffs book is marbled with detail, and performs a useful analytic service for readers trying to understand new tech foods: while many novel food companies claim to break out of the paradigms set by Big Food (those huge international companies that fill the central aisles of grocery stores with processed stuff ), Zimberoff shows that many of their founders hope to sell ingredients to Big Food, and use processing techniques that Big Food perfected or they may plan to sell the whole company to Big Food, lock, stock, and bioreactors.

As I followed Zimberoffs journey from one warehouse-based company to another, from algae to fungi, from pea protein to vegan milk and eggs, from plant-based burgers to vertical farming, and all the way to cultured meat, I found myself thinking back to Goldenweisers essay. How can we tell if a given novel food technology represents innovation, the change that changes everything, or if it represents involution, a change that ultimately changes nothing within enduring cultural, economic, and social patterns? Disclosure: I appear briefly in Technically Food as an expert on cultured meat, the subject of my own 2019 book, Meat Planet: Artificial Flesh and the Future of Food; Zimberoff spoke with me several times during her research. I spent years conducting fieldwork with tissue engineers and other scientists, as well as with entrepreneurs and futures consultants, who hope to grow animal muscle and fat, consumable as meat, from biopsies of cells, obviating the need for industrial animal agriculture. Hypothetically, cultured meat would require vastly fewer natural resources, and cause no cruelty to animals at all. We could visit a pig on a farm, eat meat grown from a biopsy of its cells, and then play with that same pig. If this effort succeeds, I believe it will constitute the largest and fastest shift in human subsistence strategies in history. Watch your step. That initial if is a doozy.

Innovation or involution? Form is the first clue. The wonder foods in Zimberoffs book mostly imitate familiar foods like chips, puffs, bars, shakes, and burgers. They may be made of new materials, but those materials do not dictate their shape. A plant-based sausage, with its arbitrary relationship between form and material, is in fact a skeuomorph, a Greek term which more or less means vessel-form. Its shape is like a container that used to be filled with other stuff, stuff that dictated the original form of the container consider those lintels of ancient Greek temples that rendered, in stone, the ends of protruding wood beams. Where pig intestines once gave sausage its shape, cultural expectation now dictates a cylinder, tapered where the traditional length of intestine was tied off at the ends. The compass in a smartphone doesnt work the way a magnetized needle does, but the digital representation of the compass on the phones screen is familiar, expected. The shapes of meat surrogate products, whether they are based on plant or animal cells, now come not from the bodies of animals, nor from the inspiration of corporate sculptors (should such a professional category exist outside my fantasy life), but from the imagined desires of consumers: burgers, sausages, chicken nuggets. Formally speaking, then, there is something involuted about the new food products Zimberoff documents. Apparently, when you ask consumers to think of plants as meat, you first must make the plants meat-shaped. And in the process you realize that meat, in our era of industrial mass-produced cheapness, has taken on arbitrary shapes. Nuggets do not appear on the bodies of chickens, at least not healthy ones.

Theres a great deal of repetition at the food-tech nexus. Soylent, the well-known meal replacement shake, closely resembles SlimFast, the diet drink targeted at women from 1977 onward. When the company Hampton Creek, which now calls itself Eat Just, released a vegan mayonnaise product, it was nearly identical to another 1977 product (odd coincidence) called Vegenaise, resembling it so closely that the creators of Vegenaise were shocked. Some of this repetition is probably conscious; Follow Your Heart, the maker of Vegenaise, has been around for a long time. And some of it may stem from entrepreneurs simply following a common pattern of thinking, according to which the problem with our food system is not our eating habits, but the nature of our food itself. Why not keep mayonnaise but make it vegan? Why not keep drinking milk, or eating ice cream, but make it from milk proteins we grow in a lab? What if we could get our artificial dyes, not to mention our protein powder, from algae? Some companies are making mycelium steaks, working with the fungus, related to mushrooms, that looks a bit like an underground network of threads. If you abstracted mycelium from the earth in which it lives, it might look like a mystical fairy network. From the standpoint of the anthropology of food, it is fascinating to notice that entrepreneurs first instinct was not to work with the natural form of those mycelium threads, to see what kind of food product might follow from that form, but instead to ask if mycelium could become an ingredient in something perceived as marketable. Throughout my research into cultured meat, I was bemused by the striking combination of inventiveness in the lab, as scientists adapted tissue culture techniques, widely used in medical research, to food production and the topological sameness of the burgers, hot dogs, and chicken nuggets that entrepreneurs hoped to produce. Theres a lot of copycat innovation not a lot of real innovation, says one of Zimberoffs interviewees, the CEO of a fungi-based meat company. Again, I recall Goldenweiser: The inevitable result is progressive complication, variety within uniformity, virtuosity within monotony.

Does all this count as involution? Taking stock, we are looking at an intense mimetic tendency, with food makers producing products that resemble each other, even if they differ in surprising ways in their raw ingredients or how they are processed. We have consistency within the pattern of seeking ever more clever ways to process foods in pursuit of value (because the greatest profit lies, as the work of food scholar Marion Nestle has shown, in processed foods). We have entrepreneurs seeking to change our products rather than the way we consume them. We have sector-wide ideological agreement that our food systems problems must be essentially technical, perhaps because technical solutions are the ones we can imagine using (and getting funded). In Meat Planet, I argue that this represents a form of imaginative closure, in which the economic, social, and ultimately political character of our food system gets obscured, because of the appeal of technological tools. This does not mean that technologies wont change our food system (indeed, if cultured meat works, it really could change everything) but that what makes the whole system of food-tech entrepreneurship work, imaginatively speaking, is the idea that technology, plus the workings of the consumer market, can provide all the change human civilization needs. Another way to express this imaginative closure may be in terms of involution. I must consider a straightforward objection to such claims. Goldenweiser thought that involution means that pattern checks creativity and development. But much of the work done at the food-tech nexus is mightily creative, and sometimes involves new ways of solving problems having to do with texture and flavor. Innovation surely describes this. Snackland is not bereft of ideas. A fair view of involution and innovation at the food-tech nexus might be that the nexus displays both traits at once. And yet involution always seems to win, because the creativity and inventiveness of food scientists takes place within economic systems they cannot contest, and usually do not want to. The nature of involution, for Goldenweiser, is that we cannot see outside a pattern, and here the salient pattern is a model of production, consumption, and value seeking that we often shorthand to capitalism.

In his 2006 book Meals to Come: A History of the Future of Food, historian Warren Belasco chronicles a set of long-running debates about the future of food, debates that have run through universities, think tanks, and into the public realm of journalism. A few major schools of thought have dominated those debates. There are Malthusians, who believe that increases in agricultural yields (due to technological progress, perhaps) tend to fall behind increases in population, because the former rises arithmetically and the latter geometrically. This means that the poorest members of any society will be exposed to malnutrition and that we have compelling reasons to impose artificial limits on population growth. There are Cornucopians who believe that technological progress will in fact outpace population growth, producing enough for all, possibly without limit. Then there is a third group, more equality-minded, who believe that the solution to problems in the food system is not a matter of managing supply and demand, but achieving more equal distribution of what we produce through better governance. The debate between the three positions began in the late 18th century, and while Malthusianism has always been influential it helped shape the food policy of the British Empire, since Thomas Robert Malthus himself taught at the school run by the British East India Company it is in Cornucopianisms belly that we effectively live and work today, getting slowly ceviched by its digestive juices. Those who work at the food-tech nexus are trying to keep Cornucopianism alive (although they may not identify with that term at all) in a new millennium, as the pressures of environmental crisis loom large. Cornucopians dream of a world with nothing but upside we save the environment and our market economies, predicated on growth, all at once. I was reminded of this when one of the companies trying to make cultured meat, previously called Memphis Meats (but based in Berkeley) rebranded as UPSIDE Foods. If you uncase a Pringles Wavy Potato Crisp and examine it from the right angle, it looks like a smiley face.

Cultured meat displays involution and innovation at once. Its researchers display great creativity in their technical efforts to take animal muscle stem cells, as well as fat cells, and induce them to grow in vitro, adapting a technique called tissue culture, which itself dates back to the early 20th century, to food production. They play with scaffolds on which animal cells can grow; they search for ideal growth media to feed their cells; they ask if it might be advantageous to combine the cells of different species in a single piece of meat, because one speciess cell line seems to produce better fat, the other better muscle, under laboratory conditions. And yet this work unfolds within a set of assumptions about the shape of meat, and appetites for meat, not to mention the assumptions that the combined powers of technology and the market will solve our human problems. In 2019, a chemical engineer named Dave Humbird was hired to conduct a feasibility study for cultured meat. I spoke with Humbird as he pursued his research and wrote his report. While other researchers have conducted feasibility studies and lifecycle analyses for cultured meat, Humbirds was the first by a scientist with no material or ideological investment in the proposition of cultured meat. His conclusions were not encouraging for anyone who hopes that cultured meat will work at scale, its costs eventually decreasing enough that it undercuts and supersedes conventional meat. Humbird found challenges both economic and technical some of the latter derived from the kinds of physical stresses on cells grown in very large bioreactors, and some of the former derived from the costs of raw ingredients. Both strongly suggest that cultured meat might never scale effectively. But I was also intrigued by Humbirds observation, relayed to me conversationally, that very few people involved with the nascent cultured meat industry either as entrepreneurs or as investors contacted him about his study, or spoke openly about his findings, even to challenge them. This fit a pattern I had long observed during my fieldwork, namely that despite the considerable hype around cultured meat, there is relatively little balanced public discussion of its technical feasibility. This could be because the startups would find no strategic advantage in such discussion, or because they simply do not have the time or resources for it.

The anthropologist Clifford Geertz turned Goldenweisers involution into agricultural involution in a 1963 book of that title, Agricultural Involution: The Process of Ecological Change in Indonesia. That book, vastly better known than Goldenweisers original essay (and challenged by many critics over the years), applies involution to Indonesian rice paddy farming from the 19th century into the 20th, with Geertz observing how Javanese peasants tried to adapt themselves to a Dutch colonial system that sought to extract value from their land and labor. According to Geertz, agricultural involution happens when farming technology and technique remain at a standstill, even as more labor flows into the system, ultimately yielding ever more complex social arrangements around work. The result is a kind of shared poverty as more and more laborers subdivide the available work. Social arrangements become Byzantine. Where Goldenweiser focused on ritual and aesthetic examples of involution, Geertz used the concept to describe how one kind of innovation, namely shifting social arrangements between peasant workers and landowners, unfolded within the limitations of Javanese agricultures technological standstill. The food-tech nexus that Zimberoff charts displays a different style of involution: technological innovation, to the point of virtuosity, within a larger limiting pattern. Call that pattern our collective difficulty recognizing the political and social character of the food system itself.

Involution is a capacious metaphor. In the work of the anthropologist Xiang Biao, involution (neijuan) describes the predicament of contemporary Chinese society, in which the middle classes and elites are locked in a struggle to pass wealth and advantage on to the next generation: only certain jobs can facilitate this process, and only certain paths of training and accomplishment lead to those jobs. Here the frame or pattern in which involution curls into complexity is determined by the narrow set of conditions for an acceptable life. The social, psychological, and material costs of failure of falling off the social treadmill are very high. Xiang Biaos version of involution shares, with Geertz and Goldenweiser, a sense of stuckness. Every story about involution implicitly conjures a form of change or progress that involution blocks. In Zimberoffs Technically Food, food-tech entrepreneurs pursue value in niches and crevasses that Big Food previously ignored, but rather than progress, their work seems like a desperate effort to keep food habits, forms, and economies afloat as climate change diminishes our available farmland and water. Every strategy in food futurism is a form of imaginative closure. The question facing us in food technology is how to tell innovation from involution and recognize how the two modes feed upon each other.

I have been saving the hardest part for last: when I say that a new food technology counts as innovation or involution, I am making a value claim, just as Goldenweiser and then Geertz and then Xiang Biao have done. But food systems are complex and social things, and political too; an individuals value claim does next to nothing. The challenge is to establish conversations about what human communities find valuable in food. Agreeing about norms is often harder than agreeing about facts. Some approaches to the future of food try to advance individual human health; others try to feed as many as possible, based on their assumptions about what counts as a sufficient diet; others presume that there are natural limits to how many of us can share the planet at once. Why not end with a question: was Reyner Banhams bag of chips a case of innovation or involution? The brilliance of his short essay was to show that the vernacular meaning of industrial foods the curling chip; the bursting, crinkling bag escapes our designs.

Benjamin Aldes Wurgaft is the author of Meat Planet: Artificial Flesh and the Future of Food.

See the original post:
The Involuted Palate, or the Savage Crinkle of Future Snacks - lareviewofbooks

Read More...

Time to Go Sushi With Cellular Salmon; When Pet Owners Tire of Their Minions – The SandPaper

August 17th, 2021 1:51 am

Sushi-loving diners in Callie will soon be partaking of test-tube salmon, compliments of San Francisco-based firm Wildtype. The company touts itself as Building a better food system by pioneering cellular agriculture to grow delicious cuts of our favorite seafood no fishing or fish farming required. I know, just when you think life cant get any weirder.

The companys website hypes its cutting-edge efforts as reinventing seafood, with a clever emphasis on inventing, since the entire process has come about through lab experimentation on handpicked cells of salmon, in the vein of stem cell exploration.

The seeds of Wildtypes chunks seed money has already been gotten aplenty comes via the choicest cells of the finest wild salmon, including king salmon, the finest and fattiest known. Once cells have been adroitly procured, the cellular growing process is on, as the meat of the matter is grown upon a type of organic plant-based scaffolding until done or ripe or something.

The plant-based scaffolding we provide for the cells to grow on, along with all the necessary nutrients like sugars, amino acids, and fats we deliver in solution, allows for the formation of the complex textures that were able to create for all types of sushi products spanning sashimi, nigiri and maki rolls, explains the companys cofounder Ary Elfenbein, a cardiologist and molecular biologist.

Wildtypes test-tube salmon is rather frighteningly identical to the real swimming thing, with a fat composition like the donor fish, including levels of healthy omega-3 fatty acids, but none of the heavy metals, microplastics, parasites, or antibiotics found in most salmon, per the companys website.

One of this methods claims to fame is how it might reduce the need for environmentally suspect fish farming.

Net pens used in fish farming pollute sensitive coastal waterways with concentrated excrement. Many farms have had escape events, introducing invasive species into sensitive ecosystems that compete with local fish populations, company cofounder Justin Kolbeck recently told Forbes magazine.

It should be emphasized this grown-in-house fish product is not even remotely related to soy-based imitation seafood and meats. The end products DNA makeup is salmon all the way; theres simply no energy wasted on the little things, like growing skeletons, scales, internal organs or brains.

Anyone remember the sci-fi thriller The Blob? Just asking for no particular reason.

To buttress Kolbecks point about escape, its profoundly unlikely that a chunk of Wildtype salmon will ooze out of the lab, leaving behind a telltale slime trail along the escape route before seeping seaward to freedom. Of course, should that happen, it would be quite a hook-up sight for any angler reeling in a big chunk of raw salmon meat. Anyone know how to clean this thing? Oh, wait, now that I think about it

OK, should we buy into this New Age salmon meat when it hits close to home? It will hit select market by next month or so, after which the company hopes to eventually produce tons and tons of its highly salmonesque stuff. Also, reports indicate other companies are champing at the test tube to get in on cellular seafood.

Personally, I somewhat prefer my seafood has seen the sea. That said, there is no doubt lab-grown seafood could be a healthy alternative to our overfishing of the worlds oceans. I can even foresee both wild-caught salmon and the beaker-based variety being served at a meal and folks clearly preferring the Wildtype offering, calling the natural too gamey.

As to the early taste tests of freshly picked/harvested Wildtype salmon, even educated buds are giving it flying colors speaking of which, the color of Wildtype salmon is identical to the donor fishs flesh color since it is the exact same fish again with the DNA thing.

For you travelers, if youre out San Fran way, the Wildtype company is all but begging folks to stop on in.

Wildtype wants to establish a high standard of education, trust, and transparency with our customers and the public. We want to show people where their food comes from and how its made, offer the owners.

Ill wax snarky by wondering if it might not be best to place test-tube salmon making in the same realm as, say, scrapple making. Philly folks get my dont ask/dont tell drift.

By the by, there have been some unique growing pains to developing a better bodiless salmon. For some unknown cell binding reason, the first chunks did not take at all well to cooking. The meat broke into what might be called individual component parts hundreds of tiny undefinable pieces of salmon essence. I cant imagine what that would have looked like and I would surely have been the only one in the lab laughing my ass off.

The last I heard, the creative minds of the company are tweaking the growing process so we can someday buy San Fran salmon for more than just sashimi, sushi and sausages.

I will absolutely be among the early-on buyers of salmon a la lab. One problem I see is naming the stuff with full disclosure in tow. There must be a distinct, immediately recognizable terminology. Ill be the first to admit that test-tube salmon would be off-putting. Less so would be manmade salmon or sea-free salmon. The company itself might run with cellular salmon, based on its self-hype that Wildtype is pioneering cellular agriculture to grow delicious cuts of our favorite seafood no fishing or fish farming required.

ECO-UGLY ABANDONMENT: I need to combine two tales in one since both have to do with mankind unloosing nonindigenous species into our delicate Pinelands environment.

The more recent of the two comes via a jungle-ish find by Division of Fish and Wildlife conservation officers. While on patrol, the officers came across your everyday boa constrictor crossing a dirt road. Yes, its everyday if you live in frickin Central America!

The 4-footer was found in a state Wildlife Management Area. Id safely venture to say it was not simply taking in the sights of our outback before making the long slither back to some tropical rainforest.

Forgoing the other minuscule possibility that the boas owner had simply been out walking it only to have his minion slip its leash, this was an all too familiar case of someone ignobly abandoning a faithful critter even after it had dedicated its entire life to being a family-member pet.

OK, that might sound a bit overemotional, but such dump-offs are a lousy trick by incompetent-as-s*** pet owners.

As to what would have become of the tropical snake had it not come back to the road looking for its human buddy, I believe it was Jack London who morbidly suggested that freezing to death isnt the worst way to go. Winter would have ended the snakes unwanted flirtation with untamed freedom.

There was no chance the lone boa could have led to the Pinelands becoming a covey of constrictors even if the captured boa wore a boa, meaning it was a female.

That tale roundaboutly leads to a twinish tale of the time piranhas swam about in Stafford Forge Lake.

It was July 2007 when I got word of weird fish being caught in the historic lake, former home to a forge and cranberry bogs. As I wrote back then, A number of piranhas were recently taken by an angler using Bass Stoppers, a favorite freshwater rig. And these werent minor models of this highly nonindigenous species. One piranha was way hefty.

I recall my well-founded disbelief upon seeing the first photo of the landing. At mere first glance, I knew this hookup was a member of a world-renowned fish family that includes piranha, pacu and oscars. To me, it was clearly a piranha.

So, what in bloody hell was such a species doing in the tannin-laced, temperate zone waters of the Forge?

The answer was all too obvious: Some numbnut had released it after it had outgrown its aquarium and its welcome. Such dumpings, while displaying a touch of compassion when compared to a toilet flush-down, are quite common. In fact, many state waters are now plagued by introduced carp, the leave-behinds from anglers using cheap so-called feeder goldfish to live-line for largemouth bass and pickerel.

The sacrificial goldfish, small carp in essence, either get off the hook or are poured into lakes at the end of a fishing session. They grow rapidly into immense vegetation bottom feeders. Once established, they create such a bottom stir that it can muck up the water, impacting gamefish, which feed by sight. They also inadvertently mosey over bass and sunfish nests hollows in the sand inadvertently sucking up eggs and newborns.

As to the Forge piranhas, the hookups led to an utterly surprising finding that they had surely been there more than just one season. The hardy little devils were showing signs of prospering, likely going into a torpor state when the lake froze in winter. Fears arose as to what they were thriving upon, assuredly indigenous species.

The realization that piranhas were making themselves at home in a New Jersey lake led to fear regarding the many people and pets commonly wading right where the fish were caught. Such frets were a bit unfounded. While packs of piranhas can go gruesomely gonzo over the smell of blood and raw flesh, Ive seen naked native children in Brazil freely swim among them, with nary a single natural bris being reported. Nonetheless, N.J. Fish and Wildlife folks went on one weird-ass search-and-destroy mission by electrocuting the lake. The method shocked the hell out of the lakes inhabitants, causing them to rise woozily to the surface, where any species non grata could be removed and apologies offered to acceptable lake occupants, which quickly recovered from the buzz, all wondering What the hell was that all about?!

RUNDOWN: Weirdly, the blowfish are back in town, mainly the far west side of Barnegat Bay where they had been, then left, only to be replaced by a ton of all new puffers moving in from waters to our north. It is once again possible to best a hundred or more per chumming session.

There are also small weaks and kingfish entering the chum slick.

Weirdest chum-related hookup was a massive black drum estimated by Paul P. at 50 pounds. It was almost landed, net hovering above, before the tiny hook gave way. That is pretty far north for Barnegat Bay black drum.

Speaking of drum, its about time for red drum to make beachline passes. The state record remains at 55 pounds, a fish taken in Great Bay by Daniel Yanino in 1985.

This is an amazing time of year to chum with grass shrimp in places like Myers Hole and surely some deeper waters toward Little Egg Inlet. Such panfishing often offers as great a variety of fish species as youll ever hook during one Jersey sitting.

Considering most of the fish drawn to a shrimp chum will be juveniles, you must use circle hooks and unhook undersized fish as quickly and gently as possible. Best bet is to not even bring them aboard. A nice series of photos can be taken without fish having to pass over the gunnel.

Surfside fluking is fair. Its best when waters are at least a bit roiled. Calm, crystal-clear water periods seem to knock down the flattie action. Every now and again there is a sudsy doormat taken.

Stingrays have glided a bit north, though a few are still quite obvious along the clear-water shoreline. Ive gotten two emails regarding ways to cook ray wings. Ill give them a try. If my taste buds salute, Ill pass them on.

Triggerfish are making their typical late-summer presence known. Some nice-sized ones mixed in, way larger than they usually show down south, re-begging the question of whether these fish go back to the Deep South or move off shore for the winter. The average sheepshead size up here dwarfs the typical sheepsheads in places like the Indian and Banana rivers in Florida.

Please do not try to fillet triggers. Too much meat is utterly wasted. After gutting, simply cook them whole. Once done and they bake very quickly with skin still on pull off the now easily removed skin and dine on the delicate white meat within. Of note, there are some filefish being labeled triggerfish. They are different to a degree, but are surprisingly similar in taste.

jaymann@thesandpaper.net

Read the original here:
Time to Go Sushi With Cellular Salmon; When Pet Owners Tire of Their Minions - The SandPaper

Read More...

Impact of microbial contamination of haematopoietic stem cells on post-transplant outcomes: A retrospective study from tertiary care centre in India -…

August 17th, 2021 1:51 am

This article was originally published here

Transfus Med. 2021 Aug 15. doi: 10.1111/tme.12805. Online ahead of print.

ABSTRACT

BACKGROUND: Haematopoietic stem cells (HSC) may act as a source of infection for the recipient due to manipulation at multiple levels from collection to infusion. Due to the high risk of contamination cultures are usually taken during multiple steps. The clinical significance of microbial contamination of HSC on the post-transplant course and the role of prophylactic antibiotics is relatively unknown.

AIMS AND METHODS: The aim of our study is to investigate the incidence of microbial contamination of haematopoietic stem cell and to assess its impact on the post-transplant febrile neutropenia, engraftment kinetics, hospitalisation and day 100 mortality. Details of all patients admitted in the bone marrow transplantation unit of a tertiary care centre in India between January 2014 and December 2018 were collected from case records.

RESULTS: Of the 1306 stem cell harvests from 503 patients sent for culture, 17 harvests (1.3%) were found to have a culture positive report. Sixteen patients had undergone autologous transplant. Multiple myeloma was most common indication of HSC transplant followed by Non-Hodgkin Lymphoma (NHL). Twelve of 17 HSC cultures were positive at the time of infusion and five were positive at the time of harvest. The five HSC that were culture positive at the time of harvest were culture negative at the time of infusion. Gram-positive organisms were isolated in six cultures and gram-negative in rest. All patients developed febrile neutropenia post-transplantation between day 1 and day 7. The median time of onset of fever was day +5 (1-7), the median duration of fever was 4 days (2-7), the median duration of antibiotic use was 11 days (9-16). Median day for neutrophil engraftment was 11 days (9-16), the median day for platelet engraftment was 14 days (10-25) and median duration of hospitalisation was 15 days (12-78). All patients were alive at day 100 of transplant.

CONCLUSION: This study shows that there appears to be minimal impact of culture positive HSC on transplant related outcomes in terms of engraftment kinetics, duration of hospitalisation and day 100 mortality. Discarding of contaminated HSC may not be required, though on development of febrile neutropenia appropriate antibiotics should be administered based on sensitivity pattern of HSC culture. Larger prospective studies are needed to determine the clinical relevance of such contaminations. Emphasis should be laid on better infection control practices to minimise contamination rates.

PMID:34396610 | DOI:10.1111/tme.12805

Read the original here:
Impact of microbial contamination of haematopoietic stem cells on post-transplant outcomes: A retrospective study from tertiary care centre in India -...

Read More...

Longeveron: Time to Buy the Di – GuruFocus.com

August 17th, 2021 1:50 am

Longeveron Inc. (LGVN, Financial) is an emerging clinical-stage biotechnology player that utilizes stem cell research. It is working towards developing regenerative medication via allogeneic mesenchymal stem cells. It is in the progress of building a number of cellular therapies at its facility, utilizing healthy bone marrow of adult donors to develop treatments for aging and aging-related diseases like Alzheimers Disease.

The companys lead candidate is a therapy known as Lomecel-B, an allogeneic product containing medicinal signaling cells from the adult donor bone marrow (from an 18 to 45 age group) and culture expanded in the companys cell processing facility. They identify and use cells with regenerative properties to build a therapy that could carry out various functions, including tissue repair and organ maintenance.

Longeveron has been in the news recently as it released the data of the Phase 2b aging frailty trials for Lomecel-B. The results did not live up to expectations, causing the stock to plunge. However, the long-term prospects of the company have not changed, in my opinion, which could mean now is a great opportunity to buy the dip.

The Phase 2b trial data

Longeveron carried out a multi-center study to assess the effect of its lead candidate Lomecel-B therapy on 148 random subjects. Its trial was partially funded by an SBIR (Small Business Innovation Research) grant from the National Institute of Aging. The company carried out a single peripheral intravenous infusion of the lead candidate in various quantities ranging from 25 million to 200 million cells. It kept the subjects under observation for 52 weeks to evaluate the efficacy and safety of the therapy. The management performed a six-minute walk test on the subjects to assess their exercise tolerance and endurance in order to evaluate the impact of the treatment. This test also analyzed gait speed, short physical performance battery, grip strength, performance-oriented mobility assessment, sexual function, cognition, depression and other factors associated with the subjects in their daily lives.

Longeveron did not see statistically significant results compared to the placebo after 180 days, which is what has disappointed investors and led to the recent selloff. However, the management saw a significant difference from placebo after 270 days of the treatment. Moreover, Lomecel-B continues to demonstrate a high level of safety as no patients showed signs of any severe adverse conditions.

The information is sufficient for Longeveron to continue pursuing their research aggressively, not just in the U.S. but in other countries as well. The management aims to initiate the Phase 2 Japanese Aging Frailty trial this year while waiting for the results of Phase 1/2 HERA trial data. The 'HERA' trial data is expected to evaluate the effects of Lomecel-B on the immune response to influenza vaccination in Aging Frailty subjects.

The importance of aging and frailty research

Aging Frailty-oriented research is gaining a very high amount of importance because of its substantial addressable market. Most patients who suffer from it show symptoms like muscle loss and decreased strength, low-level activity, slow walking, poor energy level and endurance, weight loss, nutritional deficiencies and fatigue. It has a negative impact on muscle and bone tissue health. Apart from muscles and bones, aging and frailty also negatively affects the cardiovascular system, immune system and cognition.

Stem cell treatments for aging-associated diseases are a crucial area of research given the ageing population. However, there are no FDA approved stem cell treatments in the U.S. within this domain. The potential addressable market for aging and frailty is rising sharply due to the gradual increase in average life expectancy as well as declining birth rates. Longeveron is one of the key movers in this domain and has shown significant results through their Lomecel-B therapy trials.

While the trials may not have shown a statistically significant result in a 180-day period, the 270-day data is extremely encouraging for the companys future. Furthermore, if the Lomecel-B trials continue to show success in the upcoming quarters, Longeveron could become a top candidate for a large pharma acquisition.

Is the crash justified?

Longeverons stock crashed after the companys Phase 2b press release came out, but is this crash justified? The trial results may not have been positive for a 180-day time horizon as hoped, but the 270-day results have been encouraging. Moreover, given the fact that the safety of Lomecel-B has been unquestionable, this implies that the company can go ahead with other trials (including the Phase 2 trial for aging and frailty in the Japanese market) with great confidence.

There is also a huge upside potential with respect to the future prospects of Lomecel-Bs application in Alzheimers Disease and other ageing-related diseases. Last but not the least, the company has sufficient cash to go through with multiple trials across different geographies. Thus, I believe that the recent crash in Longeverons stock price is no reason for investors to panic. Moreover, biotech microcap investors with a high risk appetite could see this drop as an investment opportunity.

See the rest here:
Longeveron: Time to Buy the Di - GuruFocus.com

Read More...

The latest on the Covid-19 pandemic in the US: Live updates – CNN

August 17th, 2021 1:50 am

The Department of Education is sending letters to the governors of Texas and Florida, as well as Florida school district superintendents, amid an escalating battle between the White House and state officials over school mask guidance as the Delta variant surges.

In a new letter Friday, Education Secretary Miguel Cardona wrote to Republican Gov. Ron DeSantis of Florida that he is deeply concerned by the states executive order restricting the implementation of school mask mandates. Cardona also took aim at the recent threat from the governors office that the state board of education could move towithhold the salariesof superintendents and school board members who disregard his executive order.

Cardona sent a similar warning to Texas Republican Gov. Greg Abbott and the states education commissioner Mike Morath, underscoring how Texass recent actions to block school districts from voluntarily adopting science-based strategies for preventing the spread of COVID-19 that are aligned with the guidance from the Centers for Disease Control and Prevention (CDC) puts these goals at risk and may infringe upon a school districts authority to adopt policies to protect students and educators as they develop their safe return to in-person instruction plans required by Federal law.

This follows statements from White House press secretary Jen Psaki earlier this week, whotold reportersthat the White House and federal government are continuing to look for ways to support local school districts and educators in Florida, as they try to follow the science do the right thing and save lives.

Psaki said later that paying for salaries could be a part of that, and the Department of Education is looking at options. Withholding funds is not the intention, she said.

Previously, Biden and members of his administration havespecificallytargetedthe governors of Florida and Texas for standing in the way of mask and vaccine requirements, pointing to the extraordinary amount of Covid-19 cases and hospitalizations in their states.

In Fridays letter to DeSantis and Corcoran, Cardona pointed to how Florida school districts can use funds from federal Covid relief for educators salaries, noting that any threat by Florida to withhold salaries from superintendents and school board members who are working to protect students and educators (or to levy other financial penalties) can be addressed using ESSER funds at the sole and complete discretion of Florida school districts.

In the letter to Florida school district superintendents, Cardona further emphasized the administrations support, saying, I want you to know that the U.S. Department of Education stands with you. Your decisions are vital to safely reopen schools and maintain safe in-person instruction, and they are undoubtedly in the best interest of your students.

Read more here:
The latest on the Covid-19 pandemic in the US: Live updates - CNN

Read More...

How this Holocaust refugee beat Covid-19 against all odds J. – The Jewish News of Northern California

August 17th, 2021 1:50 am

Vitali Voskoboiniks bright blue eyes sparkled behind his glasses as he sat in his sunny Pacifica apartment. At 79, the Holocaust refugee looked full of life; he laughed and smiled, introducing himself first in Russian, then in Hebrew, and then in English.

One would never guess that just a few months ago he was bedridden, unable to breathe independently or speak, and on the brink of death from a severe case of Covid-19.

To me, this is a miracle, said Lena Asadov, who helped care for Voskoboinik as administrator of South San Franciscos Angel Palliative Care and Hospice, Inc.

Asadov said when she had last seen him, Voskoboinik could barely sit on the edge of his bed without collapsing, his body and lungs extremely weakened from months of illness. On July 26, he stood to greet her, and he later walked down to the garden of his home at Terrace Senior Housing two accomplishments that no one was sure he would be able to achieve.

While Voskoboinik is not yet able to resume his two-mile walks to the Pacifica pier, he has made a remarkable recovery a feat Asadov credits to Voskoboiniks fighting spirit and his daughters perseverance.

Voskoboinik was born in 1941, on a train headed to Uzbekistan as his mother was escaping Nazi-occupied Ukraine. He never met his soldier father and only knew him through a series of letters his parents exchanged before his father was killed in the war. Voskoboinik grew up in the Soviet Union, where he met his wife, and together they moved to Israel. They lived there for 20 years before coming to America in 2014.

Voskoboinik passed down his fighting spirit to his only daughter, Yulia Nedzvetski, who advocated day and night for her father after he got sick in January.

Voskoboiniks symptoms began with a cough and difficulty breathing. His condition worsened rapidly, and after six days on antibiotics Voskoboinik was rushed to the ICU at Sutter Healths Mills-Peninsula Medical Center.

Once they had stabilized him, doctors estimated he had only months to live, Nedzvetski said. She refused to accept that prognosis. She had over 30 years of nursing experience in Ukraine, Russia, Israel and the U.S., as well as education in health care management and administration from Ariel University. But she also had something even more powerful: determination to get her father well again.

I knew he would get better, said Nedzvetski, who admitted to being so focused on his recovery she refused to accept that he was in critical condition.

Strict Covid safety precautions prevented her from seeing her father, except for a few times when she came to meet with doctors after she was vaccinated, but this did not stop her from dedicating her time and energy to his care. She left her job as a case manager at the VA and, with her two sons who live in Israel, set to work researching possible treatment options once doctors told her they had done everything they could, she said.

One treatment Nedzvetski suggested was proning, a process of carefully turning a patient in respiratory distress from their back to their stomach to help improve oxygen flow. Another was to use an ECMO machine, which pumps and oxygenates a patients blood outside the body, allowing the heart and lungs to rest. But Nedzvetski said she was told it was only for patients under 65.

I came with three, four, five different treatment options and everything was a no, said Nedzvetski. Its not something we do in the U.S., its not something we do for older people.

Eventually she became so frustrated and desperate she began demonstrating outside the hospital, at one point holding a sign that read Sutter, let the Holocaust survivor get the FDA approved medicine. Although she was able to meet with the ICU director and speak with a roundtable of doctors and nurses, she said they would not approve the treatments she suggested.

Nedzvetski believes that families must advocate even more than usual for their loved ones, with hospitals overwhelmed with Covid patients and visitation restricted. She said such limited access has had a negative impact on patient care.

J. asked Sutter Health about Voskoboiniks case but the hospital declined to comment.

Nedzvetski decided it was time to move her father back home and care for him there with help. But his condition was so dire he was under sedation, on a ventilator and under constant medical watch that as far as the hospital was concerned, he could not be discharged home safely.

Hospitals are and were dealing with a lot during this time, and Yulia did her best finding every possible solution, said Traci Dobronravova, director of Seniors At Home, one of the senior care services through Jewish Family and Childrens Services.

Nedzvetski utilized the help of Brigit Jacoby, Russian bilingual senior care manager at JFCS, who connected her with chaplain Bruce D. Feldstein of Jewish Chaplaincy Services at Stanford Medicine. He helped communicate with the hospital and contacted dozens of agencies about caring for Voskoboinik at home, but almost all saw his medical condition as a costly liability.

When you get into the world of experimental treatments there are a lot of protocols you have to follow, and his case fell outside of that, Feldstein. It really looked like he would not have made it, [and] it is heart-wrenching when theres a situation where you believe they should be able to help but they cant.

Then Nedzvetski found a compassionate ear at Angel Palliative Care and Hospice. I really felt for them, Asadov said. As a Jewish person who was also born in Ukraine, I just knew I needed to do everything I could to help.

Asadov said the transition from the ICU to home was extremely difficult, and that moving a patient on a ventilator to home hospice is not common. Nedzvetski said Sutter agreed to discharge her father home under the condition that she get instruction at the hospital on how to use all of the necessary medical equipment.

Asadov and the Angel Palliative Care and Hospice team helped Nedzvetski turn her home into a makeshift ICU room, complete with a hospital bed, ventilator, feeding tube and other medical supports. Nedzvetski said the agency was there whenever she needed assistance, and that one nurse, Lora Lemenov, even left her own birthday celebration to come help.

Once home, Voskoboinik was given stem cell treatment by a private physician and three days later, according to Nedzvetski, her father began to recover.

Within the month, Voskoboinik was breathing independently. As his condition improved, Angel Palliative Care and Hospice recognized that his care goals had changed and he was in need of rehabilitation services. They were able to safely graduate him from home hospice to a rehabilitation plan with Pacifica Nursing and Rehab Center. He was discharged back home in mid-July.

Asadov hopes that Voskoboiniks story will help change the stigma around hospice care, and make people aware that the goal is to provide comfort and improve patients quality of life, even if it turns out to be their final moments.

Everyone is scared of the word hospice. They hear that and think thats it, this is the end. said Asadov. But for him, hospice wasnt the end of his life. It was a new beginning.

Visit link:
How this Holocaust refugee beat Covid-19 against all odds J. - The Jewish News of Northern California

Read More...

Trade-offs among transport, support, and storage in xylem from shrubs in a semiarid chaparral environment tested with structural equation modeling -…

August 17th, 2021 1:50 am

Significance

Plant vascular systems play a central role in global water and carbon cycles and drought resistance. These vascular systems perform multiple functions that affect the fitness of plants, and trade-offs are present among these functions. Some trade-offs are well established, but studies have not examined the full suite of functions of these complex systems. Here, we used a powerful multivariate method, structural equation modeling, to test hypotheses about the trade-offs that govern this vital and globally important tissue. We show that xylem traits are broadly governed by trade-offs related to transport, mechanical support, and storage, which are rooted in cellular structure, and that the level of dehydration experienced by plants in the field exerts a strong influence over these relationships.

The xylem in plants is specialized to transport water, mechanically support the plant body, and store water and carbohydrates. Balancing these functions leads to trade-offs that are linked to xylem structure. We proposed a multivariate hypothesis regarding the main xylem functions and tested it using structural equation modeling. We sampled 29 native shrub species from field sites in semiarid Southern California. We quantified xylem water transport (embolism resistance and transport efficiency), mechanical strength, storage of water (capacitance) and starch, minimum hydrostatic pressures (Pmin), and proportions of fibers, vessels, and parenchyma, which were treated as a latent variable representing cellular trade-offs. We found that xylem functions (transport, mechanical support, water storage, and starch storage) were independent, a result driven by Pmin. Pmin was strongly and directly or indirectly associated with all xylem functions as a hub trait. More negative Pmin was associated with increased embolism resistance and tissue strength and reduced capacitance and starch storage. We found strong support for a trade-off between embolism resistance and transport efficiency. Tissue strength was not directly associated with embolism resistance or transport efficiency, and any associations were indirect involving Pmin. With Pmin removed from the model, cellular trade-offs were central and related to all other traits. We conclude that xylem traits are broadly governed by functional trade-offs and that the Pmin experienced by plants in the field exerts a strong influence over these relationships. Angiosperm xylem contains different cell types that contribute to different functions and that underpin trade-offs.

From cells to ecosystems, biological systems are complex and span multiple scales. To fully understand such systems, multivariate analytical methods are a powerful tool (1), yet it is most common to analyze variables separately or descriptively ordinate them. One powerful multivariate analytical framework is structural equation modeling (SEM) (2, 3). Plant vascular systems represent a complex multivariate system, where many traits determine functions in direct and indirect ways and interact with one another. There is much interest in understanding xylem in a systems context (46); however, using SEM to test hypotheses of the full range of xylem function in a single model has yet to be done. A positive development is that several recent studies that have applied SEM to understanding some xylem functions and traits (79).

Xylem functions include transport of water, mechanical support, and storage of water and carbohydrates (reviewed in ref. 6). These functions are interrelated, and associations among traits arise due to mechanistic links between structure and function. This can lead to trade-offs where prowess in one trait necessarily diminishes that of another (10). Traits may also be associated for at least two other reasons: shared ancestry, or when ecological conditions select for a suite of adaptive traits in different lineages in a process called concerted convergence (11).

We present relationships among xylem traits as a multivariate hypothesis in a path diagram (Fig. 1). The path model depicts the multiple variables, and the arrows (paths) represent connections between variables that can be direct (a direct arrow from one to another) or indirect (a direct arrow to a trait that has a direct path to a second trait), where indirect effects can be as important as direct ones. There are two central elements to our hypothesized model. First, that there are different cell types that are specialized to perform xylem functions: vessels conduct water; fibers provide support; and parenchyma stores carbohydrates (see also ref. 12). The division of cellular labor mitigates some direct functional trade-offs found in species with tracheid-based vascular systems (13); nevertheless, trade-offs may arise based on the amount of tissue volume allocated to different cells (4, 14). We examined this trade-off as a latent variable in our SEM model where cellular trade-off is represented by the proportions of different cell types in cross section (Fig. 1). The second centerpiece in our hypothesis is that the hydrostatic pressure potential experienced by plants during droughts or dry periods (Pmin) exerts a mechanical strain giving rise to direct and indirect effects on all other traits (11, 15, 16). This trait is affected by the environment (amount and timing of rainfall, temperature, and soil water content and conductance), and plant traits such as water use and hydraulic conductance, with additional links to many other traits (11).

Hypothesized relationships among the various xylem functions. The arrows represent pathways between two variables. Traits may have direct effects on another trait represented by an arrow directly connecting two traits, and traits may also exert indirect effects when they are connected through an intermediate trait. Latent variables are connected to their measured traits by gray arrows. Cellular trade-off is a latent variable represented by measured fiber, parenchyma, and vessel area in cross section. Tissue strength is represented by xylem density. Omitted are any double-headed arrows for variables with correlated errors (SI Appendix).

We hypothesized that Pmin is directly associated with embolism resistance and indirectly affects hydraulic transport efficiency (Fig. 1). Emboli are gas bubbles that form in conduits that block transport during drought or following freezethaw events (4). Species have evolved broad differences in embolism resistance (xylem safety) that is under strong selection by drought when negative pressures in the xylem exceed safety thresholds, leading to dieback and mortality (1719); moreover, xylem safety is strongly associated with Pmin (20, 21).

Increased embolism resistance is directly linked to reduced hydraulic transport efficiency in a well-studied trade-off (9, 22). Efficiency of xylem refers to the mass flow rate of water for a given pressure gradient and area of tissue (xylem-specific conductivity, Ks). No species has xylem that is simultaneously highly resistant to embolism (very safe) and highly efficient (23). One reason for this is because of the pits and pit membranes that connect conduits. These cellulosic membranes have nanoscopic pores, and the smaller these pores, the more resistant they are to embolism spread; however, smaller pores and thicker membranes reduce transport efficiency (22, 24). The arrangement and connections of the network of vessels in a vascular system is also an important factor (25). Globally and across angiosperm and gymnosperm lineages, a safetyefficiency trade-off has not been supported (16); however, within a specific lineage, community, or growth form, this trade-off can occur, and understanding this context is a research priority (9, 10). Pmin and efficiency are additionally predicted to be directly related because of an effect of Pmin on vessel diameters. Larger-diameter vessels are associated with greater efficiency (26), and such vessels can take longer to develop (27). If water is limited when vessels are developing, then the diminished turgor will limit vessel size (28).

Cellular trade-offs and tissue strength may be directly affected by Pmin because extreme pressures can strain conduits to the point of buckling damage or collapse (29). This threat is minimized by thicker cell walls between conduits, smaller conduit diameters, and an extensive and supportive fiber matrix (13, 30, 31), all of which create a series of direct and indirect paths (Fig. 1). First, these factors should lead to direct associations between Pmin and tissue strength (4, 29, 32) and with cellular trade-offs. A cellular trade-off affects tissue strength because more fibers promote strength at the expense of parenchyma and vessels (6). The association between tissue strength and Pmin creates four indirect paths from tissue strength (Fig. 1). These pathways lead to associations with embolism resistance and efficiency and that are hypothesized to arise because the more negative Pmin a plant experiences, the greater the need for vessels to resist embolism (30). Additionally, efficiency is reduced because smaller-diameter vessels better resist implosion (29), and stronger vessel walls are thicker and create deeper and longer pit chambers (24). Another indirect association is between tissue strength and water storage capacity. For nonsucculent woody species, most water is stored in the lumens of fibers and stronger tissues with thick-walled fibers, and narrow lumens have lower water storage (33). A final indirect association is predicted between tissue strength and Pmin through its effect on water storage, which leads to a feedback loop among these three traits.

Storage of carbohydrates in xylem allows plants to cope with variable and uncertain environments (34). Their diverse functional roles are an area of active research (34), and they are important to understand in the context of trade-offs (6, 8). Stored carbohydrates are found in parenchyma, thus increased storage capacity requires an increase in these cells [living fibers can also be important (35, 36)], which links cellular trade-offs to carbohydrate storage. Parenchyma may be structurally diverse, but they are generally thin-walled living cells that provide the least support to vessels in resisting implosion and mechanical strains contributing to the link between cellular trade-off and tissue strength and embolism resistance (30, 37). Pmin is hypothesized to be directly linked to starch storage because species that experience more negative Pmin osmoregulate by hydrolyzing starch to simple sugars (34, 38), which should create a negative association between Pmin and starch storage.

Two other direct trade-offs are predicted between cellular trade-offs and transport efficiency and embolism resistance. Previous work has found an association between the proportion of vessels in xylem (vessel area) and transport efficiency (32) or the proportion of vessel lumen area (39). We also predicted a direct relationship between cellular trade-offs and embolism resistance. This association could arise due to direct associations between proportions of cellular traits and their importance in resisting the strain of negative pressures, or this may simply be indirect through a direct effect on tissue strength. These associations also create the potential for indirect associations of Pmin with transport efficiency and embolism resistance through association with cellular trade-offs.

We used an SEM approach to test our model and hypotheses (represented in Fig. 1). Both cellular trade-offs and Pmin were predicted to affect all other traits directly or indirectly. Evaluating both simultaneously is informative, but to understand how they affected one another, we created an additional model with Pmin removed. Our hypotheses determined the paths in the diagram and the direction of their effects; however, other formulations are possible and are discussed. We measured variables representing different xylem functions and Pmin in 29 species of chaparral shrubs from Southern California. All species were growing at field sites with a semiarid Mediterranean-type climate. This system has a protracted dry season that places considerable strain on vascular transport traits (40); moreover, the values for xylem traits found among chaparral shrubs, even co-occurring ones, span a wide range, providing abundant trait variation (21, 36). All species were sampled in the same laboratory and using the same methods, thus minimizing errors due to methods differences.

Shrub species (n = 29) were measured at four field sites in Southern California (SI Appendix, Table S1). At all sites, n = 6 different individuals were tagged for sampling for each species at that site. Our goal was to study many independent species, thus sites were selected that contained diverse species (mixed chaparral). We also selected those of a similar community type and that contained abundant individuals of the indicator species chamise (Adenostoma fasciculatum). In chaparral classification, these sites would be mixed/chamise-type chaparral (40). Sites had not experienced a burn in at least 30 y, so they contained mature shrubs. All sites have a Mediterranean-type climate with hot dry summers and cool moist winters. Precipitation is almost entirely rainfall that occurs between November and May each year, with a protracted rainless season occurring in the Summer and Fall months. For more details on the sites, see ref. 36. Most of the samples and data were collected in 2009 and 2010. The phylogeny of the sampled species was reconstructed using the phylomatic database, and it was fine-tuned using a molecular phylogeny (see ref. 36 for additional details).

We measured a suite of traits to represent xylem functions with an aim to include them in a structural equation model. In many cases, there are multiple traits that could represent a function. Because our goal was to present a simple model, we did not include all the measured traits in our model because it was overly complicated and impractical. In the following sections, we highlight the care that we took to compare methods and measures to ensure the traits we chose represented a particular xylem function. The target sample size for all measurements was n = 6 different individuals per species, and the same individuals were used throughout the study to minimize intraspecific error variation. The mean of these six samples was the unit of analysis for species. For all measured traits, we sampled healthy branches that were similarly sized (about 6 mm in diameter) and located in the sunny south side of the outer canopy to minimize branch-to-branch variation. We measured multiple variables on the same stems when possible, which included hydraulic measurements, xylem density, and anatomy. Methods are fully described for most traits. Starch storage and measures of xylem cellular proportions have been previously published (36), and methods for these traits are only briefly described with the relevant publications referenced.

Resistance to embolism of distal branches was measured using a centrifuge method. Samples were brought back to the laboratory and flushed prior to sampling (see next paragraph). This method exposes stems to increasingly negative xylem pressures and measures hydraulic conductivity (Kh) declines in response. The resistance to embolism is expressed as the negative pressure for a given percentage loss of Kh. It is common to use the pressure potential at a loss of 50% of maximum Kh (P50). Here, we used the pressure potential at a 75% loss in Kh (P75). The P50 and P75 were strongly correlated (r = 0.91, P << 0.001), so this choice did not alter the analyses. The sampling protocol followed methods that have been previously published and extensively compared to reference methods (e.g., ref. 41).

Hydraulic efficiency was measured on the same stems as used for P75. Stems were 14 cm long and were flushed for 60 min at 100 kPa with an ultrafiltered (0.01-m pore) and degassed 20 mM KCl solution. The flushing treatment removed emboli from the stem xylem. The stems were then connected to a tubing system with a pressure head of 2 to 3 kPa, and flow through the stem was collected on a four-point balance. The flow rate (kg/ s) was divided by the pressure gradient (MPa/ m) to compute the Kh of the stems. This was divided by the sapwood area to compute the xylem-specific Kh (Ks), which is a trait commonly used to represent transport efficiency. Another trait that can represent efficiency is vessel diameter. We compared our Ks data to vessel diameter to validate them. The Ks was strongly and positively correlated to vessel diameter (r = 0.78, P << 0.001).

The minimum seasonal water potential was measured on distal branchlets at the end of the Fall dry season in 2009 using a pressure chamber (Model 2000, PMS Instrument Co.). Not all sites could be sampled before rains fell in 2009, so additional sampling was completed in Fall 2010. Samples were taken at predawn and midday. In theory, the predawn values equilibrate with soil water potential, and all the organs of the plant are in equilibrium including the stem xylem pressure potential (P). The predawn and midday values were strongly correlated (r = 0.95, P << 0.001), and we report midday values as Pmin. The Pmin values can be challenging to assess in long-lived species. In chaparral systems, because of the predictable and protracted Summer/Fall dry season, it is not that difficult. The Pmin that a species experiences during a typical dry season has been found to be strongly correlated to the Pmin during high-intensity drought (r = 0.87 in ref. 21).

Xylem strength was measured in two ways. One simple estimate of tissue strength is xylem density. This was measured on the same stems used for P75 measures using Archimedes principle. Stems were debarked and depithed and saturated with water. The xylem was submerged in water on a four-point balance. The mass of water displaced, the temperature of the water, and the density of water were used to convert the displaced water mass to a volume. The xylem was then oven dried at 70 C for >3 d, and the dry mass was measured. Xylem density was expressed as tissue dry mass per volume. Modulus of rupture (MOR) of stems was measured using a mechanical properties tester (Model 3342, Instron) following the methods of ref. 30. Xylem density and MOR were strongly correlated (SI Appendix, Fig. S1), thus we chose to use xylem density for simplicity.

Water storage of xylem (capacitance) was measured by generating pressurevolume curves on debarked and depithed samples that were about 1 cm long and 6 mm diameter. This size was necessary so samples would fit into psychrometers (Model C30, Wescor Corp.). Samples were saturated with water and weighed on a four-point balance. They were then placed into psychrometers for >2 h to allow them to equilibrate. The water potential of the psychrometers was measured with a datalogger (Model CR7, Campbell Scientific). Following equilibration, the samples were removed from the chamber, and the masses of the samples were weighed and recorded. The mean mass was taken pre- and postmeasurement and the average used to represent the mass at a water potential. Samples were then air dehydrated for 1 to 5 min and resealed in the psychrometers. This process was repeated between 8 and 16 times until the water potentials were about 6 MPa (the lower limit of these psychrometers). We used an array of 18 psychrometers and, to improve accuracy, psychrometers were calibrated with four to five salt solutions each time a species was sampled. Calibrations were done at three different cooling times, which we found was valuable to measure the most negative water potentials (the longest cooling time) and to get precise readings for more hydrated samples (shorter cooling times). To determine capacitance, curves were generated plotting relative water content (RWC; fresh weight dry weight/saturated weight dry weight) on the y-axis and in response to water potential (SI Appendix, Fig. S2). Capacitance was calculated as the slope (RWC/MPa) of the linear portion of the curve between about 0.3 and 1.5 MPa.

Starch content of xylem was measured using an enzymatic method for samples collected in Fall 2009. Fall was selected because this is the seasonal point when starch storage should be close to its seasonal maximum. Stems were debarked and depithed, and the remaining xylem was ground using a ball mill, consequently, only xylem starch content was measured, which was appropriate for our focus on xylem trade-offs. The starch data we used can be found in another study where our methods are fully described (36).

The proportions of difference cell types, fibers, parenchyma, and vessels were measured in cross sections of the same stems sampled for the same stems in which hydraulic traits were measured (n = 3 to 6 stems/species). Thin sections were made using a microtome and mounted in glycerol. Samples were examined at 200 magnification with a microscope (36).

We used an SEM approach to test our multivariate hypothesis (Fig. 1). We had two latent variables in our model: cellular trade-off and tissue strength. Cellular trade-off was represented by the area of fibers, vessels, and parenchyma measured in cross section, and tissue strength was represented by xylem density. Strength of xylem can be measured in many ways and at different scales (cell to tissue), thus it made conceptual sense to treat is as a latent variable (8); however, we did not statistically analyze it as a latent variable (SI Appendix, Fig. S3). Representing cellular trade-off in this way consistently led to an impossible negative error for fiber area in our models. The negative value was always very small (0.001 to 0.006). Thus, we set fiber error to zero, which has little effect on parameter estimates when the error is very close to zero (42).

The modeling approach consisted of two parts. The first was to develop a path diagram that represented the hypothesized multivariate relationships among xylem traits (Fig. 1). In the second step, we examined if the model provided an adequate fit of the data. Prior to analysis, the data were examined in the context of parametric statistical assumptions. The data were transformed using natural log for all traits except for xylem density and water storage because the transformed relationships were less linear. The absolute value of Pmin and P75 were used (SI Appendix, Table S2). The unstandardized coefficients that we report are transformed and scaled (SI Appendix, Fig. S3). All SEM tests were run using R (R version 4.0.5) package lavaan 0.6 to 8 (43).

Statisticians recommend a larger sample size than we used for SEM models that are relatively complex; however, there are reasons why we did not collect more samples. Our data set consisted of 29 species and six replicates for most variables, so we collected 174 data points for each of the nice measured factors, all of which are time consuming to measure. Another option would be to combine available data to form a larger data set, but this is not presently possible due to lack of data for the full suite of variables that we measured.

Because of our small sample size, we adjusted our model selection criteria in some ways. The goodness of fit of the SEM model was determined by a 2 test that compared the fit of the model to a model with all predictor variables. The null hypothesis was that the tested model would not differ from the fully parameterized model, thus indication of a good model fit is P > 0.05. We report model tests from standard and BollenStine bootstrapped values that are recommended for small sample sizes (3). We also report the comparative fit index and the TuckerLewis index (TLI), where values of >0.95 suggest good model fit. After testing our hypothesized model, we found that it fit the data reasonably well, but there were some paths in the model that were not significantly supported. We ran additional models with these paths removed. We compared these models to our initial hypothesized full model using information theoretic tests (Akaike information criterion [AIC] and Bayesian information criterion [BIC]), with an emphasis on the corrected AIC (AICc), which is adjusted for small sample size. These statistics evaluate the goodness of fit of a model and parsimony. The best-fit models have lower values of AIC and BIC, and values of >|2| are better fitting models.

In additional to analyzing raw trait values, we also ran analyses on phylogenetic independent contrasts (PICs). These were calculated for all traits using branch lengths set to 1 (Mesquite version 3.61). The same processes were followed and models run using PICs.

Additional analyses included assessing the variation across our sites for the nine traits we measured. This was done using boxplots and violin plots (R package ggplot2) and by partitioning the variance of the measured traits among species nested within each site, across the different sites, and within each species (intraspecific; R package lme4 for mixed-effect models). We also analyzed the bivariate relationships among all traits using simple Pearson correlations. We conducted a network analysis that shows correlations among traits in a correlogram. We included a strength analysis that assesses the importance of a trait in a network in the context of how strongly it is correlated with the other variables. The last analysis we conducted was a principal components analysis to describe the multivariate relationships among traits (princomp function in base R and plotted with package ggbiplot). We used a scree plot to determine that two components adequately explained the variation among our traits.

We observed large differences in trait values among the 29 shrub species we analyzed. These values spanned a large proportion of the observed variation across the globe for woody species (9, 38). Sampling many different species across different field sites leads to different sources of variation (SI Appendix, Table S1). We analyzed variation within sites, across sites, and intraspecifically. The general finding was that variation among traits was wide for species sampled within each site, indicating that sites were unlikely to be exerting unique effects on the measured traits (SI Appendix, Fig. S4). This is also supported by the large proportion of overall variance contributed by species nested within site (SI Appendix, Fig. S5). One exception was for Pmin and P75, which at one site (Phantom site) did not have species with values as extremely negative as found at the other sites (SI Appendix, Fig. S4); however, this likely occurred because we did not randomly sample species within a site and instead chose unique species. The Phantom site was established last, and the site contained species that experience highly negative Pmin values, but we elected to not sample them because they were already in our data set from other sites. Moreover, this site receives the second-lowest average rainfall among the four sampled, and it also experiences hot temperatures, suggesting it is not a mesic site in our study (see ref. 36).

Significant and strong bivariate correlations were observed among many of the measured traits (Fig. 2). The extremes were Pmin, which was significantly correlated with all variables except parenchyma area, and parenchyma area, which was only correlated with one other trait (Fig. 2). Not only was Pmin correlated to most variables, it also had many strong associations (SI Appendix, Fig. S6). Fiber area was another trait with many significant and strong associations with other traits (Fig. 2 and SI Appendix, Fig. S6). Making these same comparisons with PICs generally showed the same patterns (SI Appendix, Fig. S7).

Bivariate correlations among all the traits with associated r-values and significance (*** < 0.001; ** < 0.01, * < 0.05, . < 0.10) for raw trait values, and those for PICs are in the supplemental figures (SI Appendix, Fig. S7). Cap. refers to capacitance or water storage, and Par. is short for parenchyma. P75 represents the water potential at 75% loss of hydraulic conductivity and estimates embolism resistance, and Ks is xylem specific conductivity and represents transport efficiency. Details about other traits are described in Materials and Methods.

Summarizing the multivariate relationships among these traits using principal component (PC) analysis showed clear patterns where PC1 captured the inverse relationships between safety and efficiency, tissue strength and starch storage, and vessels and fibers (SI Appendix, Fig. S8). PC2 described the inverse relationship between water storage and xylem density and parenchyma and fibers. The same patterns were apparent when analyzed using PICs (SI Appendix, Fig. S8).

The analyzed SEM model produces different types of variables and coefficients. The coefficients shown along the paths (predictors) represent the relationship between variables (Fig. 3). They are standardized and represent the change expected (positive or negative) if a predictor variable is varied by one SD. In cases where there are multiple predictors for a single trait (embolism resistance, transport efficiency, tissue strength, and starch storage), the coefficients represent partial regression coefficients. We include both standardized coefficients (Fig. 3) and unstandardized coefficients in the transformed units of the measured traits (SI Appendix, Fig. S3 and Table S2).

Results from our analyzed SEM model for raw trait values (A) and PICs (B). The weights of the solid arrows correspond to P values where the thickest is <0.001, intermediate <0.01, and thinnest is <0.05. The dotted arrows correspond to P > 0.05. The values shown along paths are standardized coefficients and SEs in parentheses (SI Appendix, Fig. S3 shows unstandardized coefficients). The variance explained (R2) is shown for each trait. Latent variables are connected to their measured traits by gray arrows. Values are not shown for xylem density because this trait is included within the tissue strength variable, and the values there apply to xylem density.

The overall hypothesized model (Fig. 1) was a good fit of the data [i.e., the fit was not significantly different from a saturated model where all the possible paths were included (Fig. 3A and SI Appendix, Fig. S3 and Table 1)]. The same was true for the model using PICs (Fig. 3B and SI Appendix, Fig. S3 and Table 1). Although the model provided adequate support for covariation among the traits, there were six paths in the model that had high P values (Fig. 3 and Table 1); moreover, the TLI was <0.95. To investigate, we created models with these paths removed and compared the effect on model fit (Table 1). For the six paths with large P values, we proceeded by removing variables with the largest P values, rerunning the model, and evaluating the effect on the P values and model fit. In all cases, removing the paths had little effect on the large P values and model fit, so we removed them all (Table 1). We found that the best-fit model was the full model minus six paths with high P values (Fig. 4 and Table 1). The path between water storage and Pmin was also not significant (P = 0.198); however, removing this path led to a poorer-fitting model (Table 1).

Model fit statistics comparing the fit of different models to our hypothesized model (full model, Fig. 2)

The best-fitting SEM models for raw trait values (A) and PICs (B). The weights of the solid arrows correspond to P values where the thickest is <0.001, intermediate <0.01, and thinnest is <0.05. The dotted arrows correspond to P = 0.198 (A) and 0.220 (B). The values shown along paths are standardized coefficients and SEs in parentheses (SI Appendix, Fig. S3 shows unstandardized coefficients). The variance explained (R2) is shown for each trait. Latent variables are connected to their measured traits by gray arrows. Values are not shown for xylem density because this trait is included within the tissue strength variable, and the values there apply to xylem density.

Among the relationships that were predicted based on our hypotheses, many were not supported by the model. The model showed that transport, tissue strength, and starch storage functions were independent of one another. An important result is that a cellular trade-off was associated with Pmin and was independent of tissue strength. This trade-off was directly linked to starch storage, but it was not associated with any other traits. A network analysis shows Pmin to be a hub trait due to the number and strength of the associations (SI Appendix, Fig. S6). Another direct predicted relationship supported was the inverse relationship (trade-off) between safety from embolism and efficiency.

The results for the raw traits and PICs were virtually identical, thus we focus on raw trait values for simplicity. The direct relationships that were not supported were those between Pmin and efficiency, tissue strength and efficiency and embolism resistance, cellular trade-off and embolism resistance, efficiency, and tissue strength. Pmin and efficiency were associated through a shared relationship with embolism resistance. Tissue strength was not directly related to either embolism resistance or efficiency, thus any relationship it has with these traits is through Pmin and possibly water storage. These indirect relationships highlight Pmin as a central parameter underlying xylem trait relationships.

To explore the influence of Pmin on trait relationships further, we created models with Pmin removed (SI Appendix, Figs. S9S11). The best-fit model was produced from three candidate models (SI Appendix, Table S3). An important result is that cellular trade-offs take on a central role, directly or indirectly affecting all other traits when Pmin is removed (SI Appendix, Figs. S9S11). A good example of how Pmin is exerting influence is between cellular trade-off and tissue strength, both of which have direct paths from Pmin (Fig. 4). In the full model with Pmin this path is insignificant, and the partial standardized regression coefficient is 0.16 (Fig. 3A), thus for every SD increase in cellular trade-off, there is a 0.16 decline in tissue strength (a result of the inverse relationship between vessel area and xylem density). In the model without Pmin, the coefficient goes to 0.47 and it is significant, a result almost entirely due to the absence of Pmin. This analysis did not support a direct association between tissue strength and embolism resistance (SI Appendix, Table S3 and Figs. S9S11).

We proposed a multivariate hypothesis regarding trade-offs in xylem function that predicted how key functional traits were interrelated. These trade-offs have been mostly evaluated individually (5, 6, 8, 37); however, none have done so as part of a multivariate testable model. Such models allow for the identification of direct and indirect relationships, as well as the dependence of traits on one another. Results using PICs were the same as those with raw trait values, suggesting that shared ancestry cannot explain the associations among our sampled traits.

We found that the xylem functions (transport, strength, water storage, and carbohydrate storage) were independent of one another, and the only trait linked to all of them was Pmin. Bivariate relationships indicated significant associations between tissue strength and embolism resistance and cellular trade-offs, but these were not supported by our final SEM model. A key reason for this result is the presence of Pmin in the model and its strong associations with nearly all traits. To explore this, we created a model with Pmin removed. In this model, a cellular trade-off was found to directly affect embolism resistance, tissue strength, and starch storage and indirectly affect efficiency and water storage (all traits in the model). This supports one of our main hypotheses that the balance between the different cell types is a central structural factor affecting xylem function; moreover, it suggests that the cellular functional divisions and the range of different cellular sizes, shapes, and wall thicknesses cannot fully overcome trade-offs (6, 31).

Taken as a whole, the effect of cellular trade-offs and tissue strength is not independent of Pmin. The relationships between embolism resistance and tissue strength and cellular trade-offs are hypothesized to occur because of the need to reinforce vessels against implosion (29, 30), which is more of a threat in species that experience more negative hydrostatic pressures and that are highly resistant to embolism. Thus, the hypothesis that predicts these relationships also predicts a lack of independence among these traits, as we found. One aspect of cellular strength not included here is direct estimate of implosion resistance of individual vessels or vessel pairs (29), which if independent of bulk tissue strength, could affect model results.

Our results highlight the central importance of Pmin as an explanatory variable (11). In the context of a trait network, Pmin is a hub trait (1). Pmin represents the level of dehydration a plant experiences, and within a similar environment and measured at midday, it integrates many plant traits such as rooting patterns (44), stomatal responses (11, 45), leaf turgor and hydraulic conductance (11), and hydraulic conductance of the plant and soil system. The hub effect of Pmin in our model of xylem traits likely occurs because it captures variability in many fundamental aspects of plant function that are associated with xylem function in an example of concerted convergence. A strong relationship between Pmin and embolism resistance is well established (20), but our study shows that tissue strength and embolism resistance and cellular trade-offs are not related independent of Pmin and that Pmin is linked to cellular trade-offs.

The association between Pmin and cellular trade-offs may arise for structural and storage reasons. A shift to containing less fibers and more parenchyma may destabilize the xylem, creating a risk of vessel implosion (30). If so, then more negative Pmin would be associated with more fiber area and reduced parenchyma and vessel area, which was supported as seen among bivariate correlations [note, parenchyma is not significant; ref. 46]. These ideas suggest a link between cellular trade-offs and tissue strength, a relationship not independent of Pmin. Shifting from less fibers to more parenchyma is also associated with greater starch storage (6, 8, 35), and starch storage is strongly associated with Pmin (36). Expressing cellular trade-offs as a latent variable described by all cell types helped to identify important relationships; however, parenchyma performs important functions beyond storage such as defense, radial transport, and refilling of tracheary elements, and these additional functions warrant further study (12, 31, 47). Different types of parenchyma cells and arrangements (axial, ray, paratracheal, contact, isolation, etc.) may associate differently with different functions and predictors (12, 31), which is likely due to functional differences among these parenchyma types (8).

Storage of xylem starch and carbohydrates is an important trait related to drought tolerance and growth (48) and plays a role in xylem refilling (49). We hypothesized that Pmin drives starch storage because starch is hydrolyzed to osmoregulate in dehydration tolerant species that experience highly negative Pmin (38, 50), and this was consistent with our data. The connection between starch storage and Pmin may drive the association between starch storage and embolism resistance (36). Understanding the dynamics of carbohydrates, including its transport, is an important area of active research (34, 50).

Water storage is the only trait in our model that affects Pmin, which gives it the potential to play a critical role in overall xylem function (50). Water storage indirectly links tissue strength to the transport functions through Pmin. Xylem density (tissue strength) correlates with many different xylem traits and ecological and life history traits (51), and its effects on water storage and Pmin are likely important in this context. One caveat is that the association between water storage and Pmin was in the best-fitting model, but it was not strongly supported (P > 0.05 for the path connecting water storage to Pmin). This is mainly due to the hypothesized complex relationship between Pmin, tissue strength, and water storage. This relationship is modeled as nonrecursive (a loop) where water storage indirectly affects itself through its effect on Pmin, which in turn affects tissue strength, then back to water storage. Feedback loops are likely important in the context of selection for and relationships among traits affecting Pmin and are an important area for further study.

Other well-supported relationships in our model are the link between Pmin and embolism resistance and the trade-off between safety from embolism and efficiency. Species widely differ in the Pmin they experience, and Pmin is correlated to drought resistance and embolism resistance (18, 52). This is consistent with the hypothesis that embolism resistance is an important trait associated with plant dehydration avoidance/tolerance strategy. Our results are also consistent with the well-studied trade-off between safety from embolism and efficiency (9). At the global scale, this relationship is weak (23), and it has been argued that the multiple traits affecting this trade-off over diverse selective environments has uncoupled these traits (16). Our study is in a semiarid ecosystem, where strong water limitation likely constrains the range of responses.

Hydraulic efficiency was only strongly and significantly associated with embolism resistance. Bivariate relationships showed some significant relationships, including an association with Pmin and cellular trade-offs (fiber area), yet none of our models suggested direct associations with hydraulic efficiency. Efficiency is indirectly associated with Pmin through a direct path between Pmin and embolism resistance, and in models without Pmin, it is similarly indirectly associated with cellular trade-offs. Pmin could directly affect efficiency if expansion of large vessels was limited by turgor pressure, especially if wider vessels take longer to develop (27); however, chaparral shrubs do not have very large vessels globally speaking (53), thus during a typical hydrological year, interspecific differences may be unlikely. Nevertheless, during a drought, there will certainly be a reduction in xylem growth increment and vessel diameter, which may be driven by Pmin.

We also did not find a direct connection between tissue strength and transport efficiency. This path was predicted to arise because of the need for denser tissues in response to Pmin. The denser tissues were hypothesized to compromise efficiency between vessels with narrower diameters and thicker walls because thicker walls increase the path length through the pits where sap flows in between vessels, and this would decrease hydraulic efficiency (24). Tissue strength is driven by fiber traits (fiber abundance and wall thickness), so angiosperms can adjust their tissue strength independent of transport. However, these relationships may manifest in lineages where the developmental connection between fiber and vessel walls is strong (24).

The ecological context for our study is likely important to understand relationships with transport efficiency. Efficient transport of xylem is broadly associated with fast acquisition and use of resources, competitive ability, and has been linked to greater photosynthetic capacity and may lead to lower construction costs of stems (23). Our study focused on shrubs in a semiarid ecosystem where xylem efficiency may be unlikely to be the primary trait affecting fitness. By contrast, limited water is a likely a primary selective force for traits associated with drought survival. As such, embolism resistance may be under stronger selection than xylem efficiency (18, 52). In ecosystems with greater resources and dominated by trees, the arrows between efficiency to other traits may reverse, whereby it becomes a predictor instead of a response variable. We tried this in the present study, and when we reversed the path between efficiency and embolism resistance in the best-fit model (Table 1), the resulting model fit was poor (2 = 37.77, df = 25, P = 0.049). Direct manipulative tests to examine questions about adaptive significance of xylem traits is an area where more research is needed.

Hypotheses underpinning trait relationships with starch storage may change when carbon gain is limited over a long period by an unfavorable environment. It is well documented that when plants are carbohydrate limited, they produce less-dense tissues (54). Thus, when carbon gain is marginal relative to carbon expenses and phloem transport is impaired (55), starch availability to cambia may be limited and drive reduced tissue density and strength (56, 57). Under such conditions, a direct link between tissue strength and embolism resistance may be important as mechanically weak vessels become vulnerable to collapse (54, 56).

We conclude that xylem traits are broadly governed by trade-offs among cellular traits related to transport, mechanical support, and storage and that the Pmin experienced by plants in the field exerts a strong influence over these relationships. While angiosperms have evolved different cell types that have different functions within the xylem, and there are important functional trade-offs associated with the relative proportions of these different cell types. The important effects of Pmin on xylem traits likely arises because it places a direct mechanical strain on tissues that requires reinforcement to avoid cellular implosion; nevertheless, Pmin can affect xylem function by other pathways and traits not considered in our model because it integrates many functional attributes of plants.

All study data are included in the article and/or SI Appendix. Previously published data were used for this work [some data were previously published in a very different format in Pratt et al. (36)].

We thank Paul Smith, Michael Clem, Christine Hayes, Evan D. MacKinnon, and Hayden Toschi, who helped collect data. This study was supported by the NSF under Grant No. IOS-0845125 to R.B.P. and NSF HRD-1547784 to R.B.P. and A.L.J. Thanks to M. Witter, K. VinZant, and M. Lardner for help with permitting field sites. Two reviewers are thanked for their helpful comments.

Author contributions: R.B.P., A.L.J., and M.F.T. designed research; R.B.P., A.L.J., M.I.P., M.E.D.G., C.A.T., and M.F.T. performed research; R.B.P., A.L.J., and M.F.T. analyzed data; and R.B.P., A.L.J., M.I.P., M.E.D.G., C.A.T., and M.F.T. wrote the paper.

The authors declare no competing interest.

This article is a PNAS Direct Submission.

This article contains supporting information online at https://www.pnas.org/lookup/suppl/doi:10.1073/pnas.2104336118/-/DCSupplemental.

View original post here:
Trade-offs among transport, support, and storage in xylem from shrubs in a semiarid chaparral environment tested with structural equation modeling -...

Read More...

Tri-State Neuropathy Centers continues to expand its peripheral neuropathy treatment practice in the tri-state area to continue its mission to help…

August 17th, 2021 1:50 am

Originally known as Neuropathy Treatment Centers of PGH, Tri-State Neuropathy Centers was established in 2013 by Dr. Shawn Richey and served patients only from their Wexford office until 2015 when expansions began. There are now five locations with three of those located in Pennsylvania (Monroeville, Washington, and Wexford), one in Poland, Ohio, and one in Weirton, West Virginia.

Approximately 30 million Americans suffer from peripheral neuropathy and its debilitating symptoms of painful cramping, burning and tingling, numbness in the feet, legs and/or hands, difficulty walking and even interruption of sleep. Tri-State Neuropathys program has had a phenomenal satisfaction rate and has seen thousands of patients suffering with peripheral neuropathy who have tried everything including potentially harmful medications and other painful testing and treatments. This can leave patients still struggling and wandering down the long road of endless disappointment.

With Tri-State Neuropathy Centers innovative treatments, patients now have hope and can have the pain associated with peripheral neuropathy addressed. We have treated over 8,000 patients with a 90% satisfaction rate, and we are confident that we can help improve most anyones life who has been affected by this devastating disease, said Dr. Shawn Richey, CEO, Tri-State Neuropathy Centers.

Tri-State Neuropathy Centers are 100% focused on helping people obtain relief from neuropathy, said Dr. Richey. Our proven treatment protocol is a PAINLESS, NON-INVASIVE AND DRUG-FREE therapy that utilizes advanced technology to reverse the horrible symptoms of peripheral neuropathy. It was once thought that there was no hope for neuropathy sufferers, and now there is.

Paula Connelly sought help in 2020 when her foot became numb after surgery. I was getting very depressed as my foot was numb on the side of the incision and it was affecting my life.I decided to meet with Tri State Neuropathy Centers for a free consultation. I have completed the program I am pain free and 90 percent better. I am 68 and a Grammy of 6 grandchildren.The treatment has helped me walk without a cane and be more active with my active family as my balance has improved tremendously.

Janine Caddys pain was progressing to the point where she couldnt walk. It seems like it became noticeable about 20 years ago. At first my feet would ache from time to time, then my feet would ache so bad that I had to limit my time standing or walking. I could no longer go hiking with my husband or just take a walk. I knew it was just a matter of time before I would need a wheelchair. I heard about Tri-State Neuropathy Centers and went for my free consultation to see if I was a candidate. To date, I see a significant improvement. I can take short walks, cook and I have even been gardening. It feels like a miracle.

Frank Smitts foot condition preventing him from enjoying his usual activities. Ten years ago I hurt my foot and it continued to get worse over the years. It got to the point that my feet were so sore and cold all the time. Outdoor activities are very important to me and I was losing the ability to do them. I felt there was no hope. A friend of mine learned of Tri StateNeuropathy Centers and I made an appointment. The results have been unbelievable. I have no more pain and my feet are no longer cold. My range of motion is so much better, and my balance is back. I am now enjoying all the outdoor activities I use to and am nearly 100% better.

If you are suffering with peripheral neuropathy, you may want to consult Tri-State Neuropathy Centers for a free evaluation. We offer the first initial consultation, examination and first treatment for FREE. We qualify patients to make sure they are candidates for our treatments, and of the over 8,000 patients we have qualified, we have an outstanding success rate, said Dr. Richey.

Patients can call 724-940-9000 to schedule an initial, no-cost consultation to determine if they qualify for the Tri-State Neuropathy Centers treatment program. Additionally, a free confidential online survey is available for patients on the Tri-State Neuropathy website (www.marydancedin.com). Each survey is reviewed by a doctor.

Sponsored content brought to you byTri-State Neuropathy Centers.

Excerpt from:
Tri-State Neuropathy Centers continues to expand its peripheral neuropathy treatment practice in the tri-state area to continue its mission to help...

Read More...

Out of Every Ten Diabetic Patient, At least Seven are Identified with Diabetic Neuropathy – BioSpace

August 17th, 2021 1:50 am

Expanding at 5.9% CAGR, Peripheral Neuropathy to Cement Dominance in Diabetic Neuropathy Treatment Market

The diabetic neuropathy market study by Fact.MR offers compelling insights into key growth drivers and restraints impacting the market through 2031. The survey offers diabetic neuropathy demand outlook and studies opportunities existing in key segments, including type and end user. It also highlights key strategies adopted by market players to increase diabetic neuropathy sales.

Fact.MR A Market Research and Competitive Intelligence Provider: As per the insights by Fact.MR, the global market for diabetic neuropathy is anticipated to rise at a CAGR of 5.6% over the forecast period 2021-2031.

Increasing prevalence of diabetes as a result of changing lifestyles and imbalanced diets is a primary factor, supporting the growth of the diabetic neuropathy market. In 2019, it was found that over 1/10th of the worlds population suffered from diabetes.

Considering this, leading manufacturers are increasingly focusing on incorporating anti-diabetic formulations within their diversified portfolio. For instance, Janssen Global Services LLC, a leading pharmaceutical company offers a wide range of drugs including NUCYNTA, NUCYNTA ER, Duragesic and INVOKANA.

These drugs include tapentadol and canagliflozin, which help in regulating the blood sugar levels. Several other leading pharmaceutical companies are expected to join the bandwagon, while expanding their portfolio. These factors will contribute towards the growth of the diabetic neuropathy market.

Request a report sample to gain comprehensive insights at

https://www.factmr.com/connectus/sample?flag=S&rep_id=4698

Among various types of disorders, peripheral neuropathy segment is gaining traction and exhibiting a higher sales of diabetic neuropathy formulations. As per the Fact.MR, demand outlook for peripheral neuropathy remains optimistic and it is set to expand at a CAGR of 5.9% over the upcoming years.

Besides these, hospitals have emerged as dominant end users owing to the availability of advanced infrastructure and healthcare expertise. Also higher footfall patients will continue supporting growth in demand across hospitals.

According to the study, North America is dominating the market for diabetic neuropathy, accounting for nearly 2/5 of the market revenue across the globe. Owing to factors such as increasing number of patients for getting treatment along with rising investment in research for the development of new drugs, the market in the region is expected to expand considerably over the forecast period 2021-2031.

Increasing emphasis on research and development pursuits along with innovations in drug combinations for fulfilling the dual purpose of providing symptomatic pain relief and preventing the progression of neuropathic processes will bolster future growth prospects, says a Fact.MR analyst.

Key Takeaways from Diabetic Neuropathy Market Survey

Key Drivers

Key Restraints

To learn more about Diabetic Neuropathy Market, you can get in touch with our Analyst at:

https://www.factmr.com/connectus/sample?flag=AE&rep_id=4698

Competitive Landscape

Diabetic neuropathy manufacturers are focusing on receiving certifications from international organizations for their new product launches.

In 2017, Pfizer announced that the U.S. Food and Drug Administration (FDA) approves STEGLATRO(ertugliflozin) tablets, an oral sodium-glucose cotransporter 2 (SGLT2)inhibitor, and the fixed-dose combination STEGLUJAN (ertugliflozin and sitagliptin) tablets

For instance, in 2020, Lupin Pharmaceuticals Inc, received tentative approval from U.S. health regulator to market type 2 diabetes drugs namely Empagliflozin and Linagliptin tablets.

Some of the leading players operating in the diabetic neuropathy market profiled by Fact.MR are:

More Valuable Insights on Diabetic Neuropathy Market

Fact.MR, in its new report, offers an unbiased analysis of the global diabetic neuropathy market, analysing forecast statistics through 2021 and beyond. The survey reveals growth projections on diabetic neuropathy market with detailed segmentation:

Key Questions Covered in the Diabetic Neuropathy Market Report

Explore Fact.MRs Coverage on the Healthcare Domain

Diabetes Diagnostics Market- The demand for diabetes diagnostics is predicted to increase as a result of the COVID-19 outbreak, which has resulted in an increase in hospitalizations. Diabetes test strips are in high demand as a result of studies that show diabetics are at a higher risk of becoming seriously ill if infected with the virus. Government investment for hospitals will help to expand the market overall by making healthcare more accessible in remote areas. The diabetes diagnostics industry will see further growth as the prevalence of obesity rises. Through 2030, the global diabetes diagnostics market will be dominated by players from North America, Asia Pacific, and Europe.

Diabetes Management Software Market- The rising prevalence of type 1 and type 2 diabetes is one of the factors driving the growth of the diabetes management software industry. Diabetes patients are growing as a result of unhealthy lifestyles, poor diets, and rising stress and tensions. As a result, in recent years, the adoption of diabetes management software has increased, resulting in a favourable impact on the diabetes management software market. Another factor driving the growth of the diabetes management software market is technological advancements. One of the most important elements driving the remarkable development in the use of diabetes management software is the increasing number of younger diabetics.

OTC Analgesics Market- Over the last few years, there has been an increase in the use of off-label medications, which are inexpensive and unapproved but effective in treating ailments. Off-label medications such as tricyclic antidepressants, antihistamines, anticonvulsants, selective serotonin reuptake inhibitors, anti-anxiety medicines, and steroids are increasingly being used to treat pain sensations. Because of the widespread availability of over-the-counter analgesics, which are administered with approved medications as maintenance therapy, symptom management linked with pain has become convenient and straightforward. The market for over-the-counter analgesics has shown to have a lot of potential all over the world.

About Fact.MR

Market research and consulting agency with a difference! Thats why 80% of Fortune 1,000 companies trust us for making their most critical decisions. We have offices in US and Dublin, whereas our global headquarter is in Dubai. While our experienced consultants employ the latest technologies to extract hard-to-find insights, we believe our USP is the trust clients have on our expertise. Spanning a wide range from automotive & industry 4.0 to healthcare & retail, our coverage is expansive, but we ensure even the most niche categories are analysed. Reach out to us with your goals, and well be an able research partner.

Contact:

Mahendra SinghUS Sales Office11140 Rockville PikeSuite 400Rockville, MD 20852United StatesTel: +1 (628) 251-1583E: sales@factmr.com

Source: Fact.MR

Read more here:
Out of Every Ten Diabetic Patient, At least Seven are Identified with Diabetic Neuropathy - BioSpace

Read More...

Page 164«..1020..163164165166..170180..»


2025 © StemCell Therapy is proudly powered by WordPress
Entries (RSS) Comments (RSS) | Violinesth by Patrick